≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback

Disorders of adrenal gland, other and/or unspecified

DOID EFO Endpoint Browser PheWeb

E4_ADRENAS

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519870

1. Apply sex-specific rule

None

519870

2. Check conditions

None

519870

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 — E27.8, E27.9
  • Hospital discharge: ICD-9 — 255[8-9]
  • Hospital discharge: ICD-8 — 2559
  • Cause of death: ICD-10 — E27.8, E27.9
  • Cause of death: ICD-9 — 255[8-9]
  • Cause of death: ICD-8 — 2559

2 out of 7 registries used, show all original rules.

199

4. Check minimum number of events

None

199

5. Include endpoints

None

199

6. Filter based on genotype QC (FinnGen only)

189

Control definitions (FinnGen only)

Control exclude
E4_ENDOGLAND

Extra metadata

Level in the ICD hierarchy
4
First used in FinnGen datafreeze
DF2

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

All Female Male
Number of individuals
Whole population 1308 813 486
Only index persons 1013 644 369
Unadjusted period prevalence (%)
Whole population 0.02 0.02 0.01
Only index persons 0.02 0.02 0.01
Median age at first event (years)
Whole population 49.81 46.38 55.27
Only index persons 49.26 46.43 54.20

-FinnGen-

Key figures

All Female Male
Number of individuals 189 117 72
Unadjusted period prevalence (%) 0.04 0.04 0.03
Median age at first event (years) 51.60 45.20 62.00

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
199
Matched controls
1990
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
H02AB09
ATC
hydrocortisone; systemic
99.8
165.4
89
16
E27.9
ICD-10 Finland
Disorder of adrenal gland, unspecified
+∞
115.1
99
*
E27.8
ICD-10 Finland
Other specified disorders of adrenal gland
+∞
62.9
57
*
Z03.80
ICD-10 Finland
Observation for other suspected diseases and conditions
21.0
52.0
42
25
105
Kela drug reimbursment
Adrenal cortical hypofunction
+∞
27.8
26
*
E27.4
ICD-10 Finland
Other and unspecified adrenocortical insufficiency
310.7
27.4
27
*
E27.1
ICD-10 Finland
Primary adrenocortical insufficiency
+∞
25.6
24
*
E27.3
ICD-10 Finland
Drug-induced adrenocortical insufficiency
+∞
24.5
23
*
H02AA02
ATC
fludrocortisone; oral
71.0
22.4
25
*
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
4.9
19.4
52
135
25599
ICD-8 Finland
Diseases of adrenal glands, Other and unspecified
+∞
15.8
15
*
JN3AD
NOMESCO Finland
Abdominal CT examination
4.2
15.0
47
136
E23.03
ICD-10 Finland
Lack of ACTH
+∞
14.8
14
*
E27.2
ICD-10 Finland
Addisonian crisis
+∞
13.7
13
*
101
Kela drug reimbursment
Anterior pituitary hypofunction
+∞
12.6
12
*
2559X
ICD-9 Finland
Disorders of adrenal glands, Unspecified disorder of adrenal glands
+∞
12.6
12
*
R10.4
ICD-10 Finland
Other and unspecified abdominal pain
2.9
12.4
99
504
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
3.7
12.2
45
145
M05BA04
ATC
alendronic acid; oral
4.6
11.9
31
77
SPAT1301
SPAT
No procedures
2.9
11.7
82
388
AA4CG
NOMESCO Finland
Extensive MRI examination of sella turcica with high intensity magnet
+∞
11.6
11
*
25598
ICD-8 Finland
Diseases of adrenal glands, Alii definiti
+∞
11.6
11
*
Z01.8
ICD-10 Finland
Other specified special examinations
3.0
11.5
66
279
R60.9
ICD-10 Finland
Oedema, unspecified
5.5
11.3
23
46
H02AB06
ATC
prednisolone; systemic
2.8
11.1
122
723
D35.0
ICD-10 Finland
Benign neoplasm: Adrenal gland
19.2
10.9
16
9
N06AX21
ATC
duloxetine; oral
3.5
10.9
44
150
R53
ICD-10 Finland
Malaise and fatigue
2.8
10.7
78
373
C03DA01
ATC
spironolactone; oral
3.6
10.7
41
135
NK6QA
NOMESCO Finland
Measurement of bone density from two or more locations with X-ray
4.5
10.6
28
70
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
2.8
10.5
78
376
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
4.1
10.3
31
86
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.6
10.1
114
673
C03CA01
ATC
furosemide; systemic
2.7
10.1
76
368
H03AA01
ATC
levothyroxine sodium; systemic
2.8
9.5
64
291
E23.00
ICD-10 Finland
Panhypopituitarism
+∞
9.4
9
*
D44.1
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Adrenal gland
19.7
9.1
13
7
M05BX04
ATC
denosumab; parenteral
4.4
8.8
23
57
NA3AA
NOMESCO Finland
Lumbar spine X-ray examination without contrast
3.6
8.6
31
97
AA1AD
NOMESCO Finland
CT of head and brain
2.5
8.6
72
362
TPH04
NOMESCO Finland
Cathetrisation of vein
2.7
8.6
60
277
E87.1
ICD-10 Finland
Hypo-osmolality and hyponatraemia
5.0
8.5
19
41
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
2.4
8.3
85
468
M54.9
ICD-10 Finland
Dorsalgia, unspecified
3.1
8.2
38
140
T78.4
ICD-10 Finland
Allergy, unspecified
5.0
8.1
18
39
N02AX02
ATC
tramadol; systemic, rectal
2.3
8.0
101
607
JN3BD
NOMESCO Finland
Extensive abdominal CT
3.5
7.9
30
97
A02BC05
ATC
esomeprazole; systemic
2.3
7.9
95
559
R02
ICPC
Shortness of breath/dyspnoea
3.0
7.8
40
156
D35.2
ICD-10 Finland
Benign neoplasm: Pituitary gland
46.9
7.8
9
*
R11
ICD-10 Finland
Nausea and vomiting
3.3
7.8
31
104
WX892
NOMESCO Finland
Monitored bed care
4.0
7.7
23
63
N03AX16
ATC
[U] pregabalin
2.5
7.6
59
284
R06.0
ICD-10 Finland
Dyspnoea
2.4
7.6
73
389
E03.9
ICD-10 Finland
Hypothyroidism, unspecified
2.9
7.5
40
159
X59
ICD-10 Finland
Exposure to unspecified factor
2.7
7.5
48
211
FB1BD
NOMESCO Finland
Extensive CT examination of arteria pulmonalis
3.8
7.4
24
70
EB1HA
NOMESCO Finland
Panorama tomography of teeth and jaws or similar X-ray examination
2.3
7.3
95
573
SPAT1230
SPAT
Aid fitting and borrowing and monitoring of use
2.8
7.2
43
181
R03BB04
ATC
tiotropium bromide; inhalant
3.2
7.1
31
110
NA3BG
NOMESCO Finland
Lumbar spine MRI examination with high intensity magnet
3.1
7.0
32
116
K59.09
ICD-10 Finland
Constipation, unspecified
3.8
6.9
22
63
R07.4
ICD-10 Finland
Chest pain, unspecified
2.3
6.9
71
386
A06AC01
ATC
ispaghula (psylla seeds); oral
2.3
6.9
67
356
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
2.7
6.9
41
173
SPAT1254
SPAT
Administration of medicine
2.7
6.8
40
167
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
3.2
6.8
29
101
A09
ICD-10 Finland
Other gastroenteritis and colitis of infectious and unspecified origin
2.5
6.7
52
249
TLC00
NOMESCO Finland
Insertion of intrauterine device
4.1
6.7
19
50
WZC00
NOMESCO Finland
Treatment plan or consultation
2.2
6.6
85
507
Z50.1
ICD-10 Finland
Other physical therapy
4.3
6.5
17
42
R03AC12
ATC
salmeterol; inhalant
4.3
6.5
17
42
A49.9
ICD-10 Finland
Bacterial infection, unspecified
2.9
6.4
33
128
2558X
ICD-9 Finland
Disorders of adrenal glands, Other specified disorders of adrenal glands
+∞
6.3
6
*
E27
ICD-10 Finland
Other disorders of adrenal gland
+∞
6.3
6
*
E27.0
ICD-10 Finland
Other adrenocortical overactivity
+∞
6.3
6
*
K21.0
ICD-10 Finland
Gastro-oesophageal reflux disease with oesophagitis
3.1
6.2
28
101
K92.0
ICD-10 Finland
Haematemesis
9.0
6.1
12
14
SPAT1223
SPAT
Implementation of physical therapy rehabilitation plan
2.2
6.1
65
356
103
Kela drug reimbursment
Diabetes, insulin-treated
2.3
6.1
58
303
D50.9
ICD-10 Finland
Iron deficiency anaemia, unspecified
3.4
6.1
23
74
E11.9
ICD-10 Finland
Type 2 diabetes mellitus, without complications
2.3
6.1
55
282
SPAT1262
SPAT
Handing over of treatment supplies
2.6
6.1
38
164

TimeCodeWAS

↥

TODO / Current known limitations:

  • Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
  • Legend / how to read the glyphs.
  • Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
  • Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
  • Download CSV.
  • No filters and sorters.
  • Limited amount of endpoints (~400) having TimeCodeWAS data.
  • Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
Endocrinology
46 [38004485]
1.8e+00
2.0e+00
2.4e+00
—
3.5e+00
3.5e+00
2.8e+00
cases:16.47%
controls:3.29%
cases:14.04%
controls:2.08%
cases:7.60%
controls:0.71%
—
—
cases:16.47%
controls:0.60%
cases:40.25%
controls:1.91%
cases:35.43%
controls:3.08%
28
55
142
1617
24
35
147
1647
13
12
158
1670
—
28
10
142
1670
64
31
95
1588
45
42
82
1320
hydrocortisone; oral, parenteral
H02AB09 [21602737]
2.7e+00
4.3e+00
—
1.0e+50
—
5.1e+00
3.6e+00
cases:14.71%
controls:1.20%
cases:18.13%
controls:0.30%
—
—
cases:4.09%
controls:0.00%
—
—
cases:37.11%
controls:0.37%
cases:33.86%
controls:1.32%
25
20
145
1652
31
5
140
1677
—
7
0
164
1682
—
59
6
100
1613
43
18
84
1344
Cortisol [Moles/volume] in Serum or Plasma
14675-3 [3036481]
2.4e+00
3.8e+00
—
1.0e+50
—
4.3e+00
3.2e+00
cases:12.35%
controls:1.32%
cases:19.30%
controls:0.54%
—
—
cases:10.53%
controls:0.00%
—
—
cases:25.16%
controls:0.43%
cases:28.35%
controls:1.54%
21
22
149
1650
33
9
138
1673
—
18
0
153
1682
—
40
7
119
1612
36
21
91
1341
pH of Serum or Plasma
2753-2 [3018418]
1.0e+00
1.7e+00
3.0e+00
1.0e+50
3.5e+00
1.6e+00
1.5e+00
cases:12.94%
controls:5.14%
cases:12.87%
controls:2.73%
cases:6.43%
controls:0.36%
cases:2.92%
controls:0.00%
cases:8.82%
controls:0.30%
cases:11.95%
controls:2.59%
cases:25.98%
controls:7.27%
22
86
148
1586
22
46
149
1636
11
6
160
1676
5
0
166
1682
15
5
155
1675
19
42
140
1577
33
99
94
1263
prednisolone; oral, parenteral
H02AB06 [21602734]
1.6e+00
2.0e+00
2.2e+00
—
3.0e+00
1.8e+00
1.4e+00
cases:34.71%
controls:9.93%
cases:22.81%
controls:3.98%
cases:5.26%
controls:0.59%
—
—
cases:7.06%
controls:0.36%
cases:20.75%
controls:4.08%
cases:33.86%
controls:11.01%
59
166
111
1506
39
67
132
1615
9
10
162
1672
—
12
6
158
1674
33
66
126
1553
43
150
84
1212
prednisolone
A07EA01 [21600653]
1.6e+00
2.0e+00
2.2e+00
—
3.0e+00
1.8e+00
1.4e+00
cases:34.71%
controls:9.93%
cases:22.81%
controls:3.98%
cases:5.26%
controls:0.59%
—
—
cases:7.06%
controls:0.36%
cases:20.75%
controls:4.14%
cases:33.86%
controls:11.01%
59
166
111
1506
39
67
132
1615
9
10
162
1672
—
12
6
158
1674
33
67
126
1552
43
150
84
1212
Internal Medicine
11 [38004456]
9.8e-01
1.6e+00
2.2e+00
—
3.2e+00
1.9e+00
1.4e+00
cases:40.59%
controls:20.39%
cases:29.24%
controls:7.61%
cases:10.53%
controls:1.25%
—
—
cases:19.41%
controls:1.01%
cases:37.74%
controls:8.15%
cases:46.46%
controls:17.77%
69
341
101
1331
50
128
121
1554
18
21
153
1661
—
33
17
137
1663
60
132
99
1487
59
242
68
1120
Sodium [Moles/volume] in Serum or Plasma
2951-2 [3019550]
3.3e-01
9.3e-01
2.3e+00
4.4e+00
2.4e+00
1.1e+00
4.4e-01
cases:41.18%
controls:33.55%
cases:44.44%
controls:23.96%
cases:33.33%
controls:4.70%
cases:22.22%
controls:0.36%
cases:30.59%
controls:3.99%
cases:51.57%
controls:26.56%
cases:59.06%
controls:48.16%
70
561
100
1111
76
403
95
1279
57
79
114
1603
38
6
133
1676
52
67
118
1613
82
430
77
1189
75
656
52
706
Potassium [Moles/volume] in Serum or Plasma
2823-3 [3023103]
3.2e-01
8.9e-01
2.3e+00
4.4e+00
2.3e+00
1.1e+00
4.3e-01
cases:41.18%
controls:33.79%
cases:43.86%
controls:24.38%
cases:33.33%
controls:4.93%
cases:22.22%
controls:0.36%
cases:30.59%
controls:4.05%
cases:51.57%
controls:26.99%
cases:59.06%
controls:48.31%
70
565
100
1107
75
410
96
1272
57
83
114
1599
38
6
133
1676
52
68
118
1612
82
437
77
1182
75
658
52
704
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma
19072-8 [3016431]
9.9e-01
1.5e+00
2.8e+00
1.0e+50
2.9e+00
1.3e+00
1.4e+00
cases:22.35%
controls:9.69%
cases:19.88%
controls:5.41%
cases:11.11%
controls:0.77%
cases:5.85%
controls:0.00%
cases:15.29%
controls:0.95%
cases:19.50%
controls:5.93%
cases:40.16%
controls:14.54%
38
162
132
1510
34
91
137
1591
19
13
152
1669
10
0
161
1682
26
16
144
1664
31
96
128
1523
51
198
76
1164
Calcium.ionized [Moles/volume] in Serum or Plasma
1995-0 [3021347]
9.4e-01
1.4e+00
2.5e+00
1.0e+50
3.0e+00
1.2e+00
1.4e+00
cases:19.41%
controls:8.61%
cases:16.37%
controls:4.82%
cases:7.60%
controls:0.65%
cases:5.26%
controls:0.00%
cases:12.94%
controls:0.71%
cases:14.47%
controls:4.82%
cases:36.22%
controls:11.89%
33
144
137
1528
28
81
143
1601
13
11
158
1671
9
0
162
1682
22
12
148
1668
23
78
136
1541
46
162
81
1200
Creatinine [Moles/volume] in Serum or Plasma
14682-9 [3020564]
3.7e-01
7.9e-01
2.2e+00
4.3e+00
2.3e+00
8.9e-01
3.5e-01
cases:45.88%
controls:36.90%
cases:46.78%
controls:28.48%
cases:36.26%
controls:6.06%
cases:23.98%
controls:0.42%
cases:33.53%
controls:5.00%
cases:52.20%
controls:31.01%
cases:60.63%
controls:51.98%
78
617
92
1055
80
479
91
1203
62
102
109
1580
41
7
130
1675
57
84
113
1596
83
502
76
1117
77
708
50
654
Pulmonary Disease
29 [38004472]
1.3e+00
1.5e+00
2.0e+00
—
1.8e+00
2.0e+00
1.6e+00
cases:25.29%
controls:8.07%
cases:16.96%
controls:4.40%
cases:5.26%
controls:0.71%
—
—
cases:5.29%
controls:0.89%
cases:25.16%
controls:4.32%
cases:30.71%
controls:8.00%
43
135
127
1537
29
74
142
1608
9
12
162
1670
—
9
15
161
1665
40
70
119
1549
39
109
88
1253
CBC panel - Blood by Automated count
58410-2 [40761511]
3.5e-01
7.0e-01
2.3e+00
4.2e+00
2.2e+00
8.3e-01
3.3e-01
cases:42.35%
controls:34.03%
cases:36.84%
controls:22.53%
cases:28.65%
controls:3.98%
cases:16.37%
controls:0.30%
cases:23.53%
controls:3.15%
cases:41.51%
controls:23.66%
cases:53.54%
controls:45.23%
72
569
98
1103
63
379
108
1303
49
67
122
1615
28
5
143
1677
40
53
130
1627
66
383
93
1236
68
616
59
746
Albumin [Mass/volume] in Serum or Plasma
1751-7 [3024561]
8.7e-01
1.1e+00
2.8e+00
—
2.2e+00
1.6e+00
1.2e+00
cases:17.65%
controls:8.25%
cases:13.45%
controls:4.88%
cases:8.19%
controls:0.54%
—
—
cases:6.47%
controls:0.77%
cases:19.50%
controls:4.69%
cases:29.92%
controls:11.23%
30
138
140
1534
23
82
148
1600
14
9
157
1673
—
11
13
159
1667
31
76
128
1543
38
153
89
1209
Troponin T.cardiac [Mass/volume] in Serum or Plasma
6598-7 [3019800]
8.1e-01
1.1e+00
2.8e+00
1.0e+50
2.6e+00
1.5e+00
9.1e-01
cases:14.71%
controls:7.12%
cases:10.53%
controls:3.63%
cases:7.60%
controls:0.48%
cases:7.60%
controls:0.00%
cases:5.88%
controls:0.48%
cases:14.47%
controls:3.77%
cases:22.05%
controls:10.21%
25
119
145
1553
18
61
153
1621
13
8
158
1674
13
0
158
1682
10
8
160
1672
23
61
136
1558
28
139
99
1223
tramadol; oral, parenteral, rectal
N02AX02 [21604298]
1.3e+00
1.6e+00
2.5e+00
—
2.7e+00
1.6e+00
6.0e-01
cases:21.76%
controls:6.94%
cases:12.28%
controls:2.85%
cases:4.68%
controls:0.42%
—
—
cases:5.88%
controls:0.42%
cases:10.69%
controls:2.29%
cases:11.81%
controls:6.83%
37
116
133
1556
21
48
150
1634
8
7
163
1675
—
10
7
160
1673
17
37
142
1582
15
93
112
1269
Erythrocytes [#/volume] in Blood
26453-1 [3026361]
2.7e-01
7.0e-01
2.0e+00
4.1e+00
2.1e+00
7.5e-01
2.2e-01
cases:47.06%
controls:40.37%
cases:49.71%
controls:33.00%
cases:37.43%
controls:7.49%
cases:22.81%
controls:0.48%
cases:33.53%
controls:6.07%
cases:53.46%
controls:35.21%
cases:62.20%
controls:56.83%
80
675
90
997
85
555
86
1127
64
126
107
1556
39
8
132
1674
57
102
113
1578
85
570
74
1049
79
774
48
588
Platelets [#/volume] in Blood
26515-7 [3007461]
2.7e-01
7.0e-01
2.0e+00
4.1e+00
2.0e+00
7.5e-01
2.0e-01
cases:47.06%
controls:40.31%
cases:49.71%
controls:33.00%
cases:37.43%
controls:7.43%
cases:22.81%
controls:0.48%
cases:32.94%
controls:6.01%
cases:53.46%
controls:35.08%
cases:61.42%
controls:56.68%
80
674
90
998
85
555
86
1127
64
125
107
1557
39
8
132
1674
56
101
114
1579
85
568
74
1051
78
772
49
590
Hematocrit [Volume Fraction] of Blood by calculation
20570-8 [3009542]
2.7e-01
6.9e-01
2.0e+00
4.1e+00
2.1e+00
7.5e-01
2.2e-01
cases:47.06%
controls:40.37%
cases:49.71%
controls:33.06%
cases:37.43%
controls:7.49%
cases:22.81%
controls:0.48%
cases:33.53%
controls:6.07%
cases:53.46%
controls:35.21%
cases:62.20%
controls:56.83%
80
675
90
997
85
556
86
1126
64
126
107
1556
39
8
132
1674
57
102
113
1578
85
570
74
1049
79
774
48
588
Leukocytes [#/volume] in Blood
26464-8 [3010813]
2.7e-01
6.9e-01
2.0e+00
4.1e+00
2.1e+00
7.5e-01
1.9e-01
cases:47.06%
controls:40.43%
cases:49.71%
controls:33.12%
cases:36.84%
controls:7.49%
cases:22.81%
controls:0.48%
cases:33.53%
controls:6.07%
cases:53.46%
controls:35.27%
cases:61.42%
controls:56.83%
80
676
90
996
85
557
86
1125
63
126
108
1556
39
8
132
1674
57
102
113
1578
85
571
74
1048
78
774
49
588
Hemoglobin [Mass/volume] in Blood
718-7 [3000963]
2.7e-01
6.7e-01
2.0e+00
4.1e+00
2.0e+00
7.5e-01
2.2e-01
cases:47.06%
controls:40.49%
cases:49.12%
controls:33.12%
cases:36.84%
controls:7.49%
cases:22.81%
controls:0.48%
cases:33.53%
controls:6.19%
cases:53.46%
controls:35.21%
cases:62.20%
controls:56.83%
80
677
90
995
84
557
87
1125
63
126
108
1556
39
8
132
1674
57
104
113
1576
85
570
74
1049
79
774
48
588
MCH [Entitic mass]
28539-5 [3035941]
2.7e-01
7.0e-01
2.0e+00
4.1e+00
2.0e+00
7.5e-01
1.9e-01
cases:47.06%
controls:40.31%
cases:49.71%
controls:33.00%
cases:36.84%
controls:7.43%
cases:22.22%
controls:0.48%
cases:32.94%
controls:6.07%
cases:53.46%
controls:35.21%
cases:61.42%
controls:56.83%
80
674
90
998
85
555
86
1127
63
125
108
1557
38
8
133
1674
56
102
114
1578
85
570
74
1049
78
774
49
588
MCV [Entitic mean volume] in Red Blood Cells
30428-7 [3024731]
2.7e-01
6.9e-01
2.0e+00
4.1e+00
2.0e+00
7.6e-01
1.9e-01
cases:47.06%
controls:40.37%
cases:49.71%
controls:33.06%
cases:36.84%
controls:7.49%
cases:22.22%
controls:0.48%
cases:32.94%
controls:6.07%
cases:53.46%
controls:35.02%
cases:61.42%
controls:56.83%
80
675
90
997
85
556
86
1126
63
126
108
1556
38
8
133
1674
56
102
114
1578
85
567
74
1052
78
774
49
588
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)/1.73 sq M
62238-1 [40764999]
3.2e-01
7.9e-01
2.0e+00
4.1e+00
1.9e+00
7.8e-01
4.6e-01
cases:31.76%
controls:25.24%
cases:35.09%
controls:19.74%
cases:24.56%
controls:4.40%
cases:15.20%
controls:0.30%
cases:19.41%
controls:3.45%
cases:38.36%
controls:22.24%
cases:51.18%
controls:39.72%
54
422
116
1250
60
332
111
1350
42
74
129
1608
26
5
145
1677
33
58
137
1622
61
360
98
1259
65
541
62
821
INR in Blood by Coagulation assay
34714-6 [3032080]
8.0e-01
1.4e+00
2.5e+00
—
2.1e+00
1.5e+00
1.2e+00
cases:19.41%
controls:9.81%
cases:18.13%
controls:5.35%
cases:14.04%
controls:1.37%
—
—
cases:10.59%
controls:1.43%
cases:21.38%
controls:5.93%
cases:31.50%
controls:12.48%
33
164
137
1508
31
90
140
1592
24
23
147
1659
—
18
24
152
1656
34
96
125
1523
40
170
87
1192
Outpatient Visit
OP [9202]
4.2e-01
8.7e-01
1.2e+00
4.6e+00
1.5e+00
1.1e+00
6.3e-01
cases:77.65%
controls:69.62%
cases:70.18%
controls:49.64%
cases:27.49%
controls:10.58%
cases:36.84%
controls:0.59%
cases:31.76%
controls:9.64%
cases:74.21%
controls:48.12%
cases:85.04%
controls:75.26%
132
1164
38
508
120
835
51
847
47
178
124
1504
63
10
108
1672
54
162
116
1518
118
779
41
840
108
1025
19
337
Inpatient Hospital
21 [8717]
6.8e-01
1.2e+00
2.2e+00
1.0e+50
2.5e+00
1.6e+00
1.0e+00
cases:43.53%
controls:28.11%
cases:22.22%
controls:8.15%
cases:9.36%
controls:1.13%
cases:19.30%
controls:0.00%
cases:11.76%
controls:1.07%
cases:29.56%
controls:7.66%
cases:42.52%
controls:20.70%
74
470
96
1202
38
137
133
1545
16
19
155
1663
33
0
138
1682
20
18
150
1662
47
124
112
1495
54
282
73
1080
Basophils/Leukocytes in Blood
30180-4 [3022096]
8.1e-01
1.2e+00
2.1e+00
—
2.8e+00
1.0e+00
1.2e+00
cases:20.59%
controls:10.35%
cases:16.96%
controls:5.59%
cases:9.36%
controls:1.25%
—
—
cases:13.53%
controls:0.95%
cases:16.35%
controls:6.73%
cases:33.86%
controls:13.00%
35
173
135
1499
29
94
142
1588
16
21
155
1661
—
23
16
147
1664
26
109
133
1510
43
177
84
1185
Inpatient Visit
IP [9201]
6.4e-01
1.4e+00
2.5e+00
1.0e+50
3.2e+00
1.1e+00
9.7e-01
cases:15.29%
controls:8.73%
cases:12.87%
controls:3.69%
cases:4.09%
controls:0.36%
cases:12.28%
controls:0.00%
cases:8.24%
controls:0.36%
cases:11.32%
controls:4.14%
cases:24.41%
controls:10.87%
26
146
144
1526
22
62
149
1620
7
6
164
1676
21
0
150
1682
14
6
156
1674
18
67
141
1552
31
148
96
1214
Lymphocytes/Leukocytes in Blood
26478-8 [3002030]
8.3e-01
1.3e+00
2.0e+00
—
2.7e+00
1.0e+00
1.2e+00
cases:21.18%
controls:10.47%
cases:18.13%
controls:5.83%
cases:8.77%
controls:1.25%
—
—
cases:13.53%
controls:1.07%
cases:16.35%
controls:6.55%
cases:34.65%
controls:13.51%
36
175
134
1497
31
98
140
1584
15
21
156
1661
—
23
18
147
1662
26
106
133
1513
44
184
83
1178
Eosinophils/Leukocytes in Blood
26450-7 [3006504]
8.0e-01
1.2e+00
2.1e+00
—
2.7e+00
9.6e-01
1.2e+00
cases:20.59%
controls:10.41%
cases:16.96%
controls:5.77%
cases:9.36%
controls:1.25%
—
—
cases:13.53%
controls:1.07%
cases:15.72%
controls:6.67%
cases:33.86%
controls:13.00%
35
174
135
1498
29
97
142
1585
16
21
155
1661
—
23
18
147
1662
25
108
134
1511
43
177
84
1185
Monocytes/Leukocytes in Blood
26485-3 [3019069]
8.1e-01
1.2e+00
2.0e+00
—
2.7e+00
9.6e-01
1.2e+00
cases:20.59%
controls:10.35%
cases:16.96%
controls:5.83%
cases:8.77%
controls:1.25%
—
—
cases:13.53%
controls:1.07%
cases:15.72%
controls:6.67%
cases:33.86%
controls:12.92%
35
173
135
1499
29
98
142
1584
15
21
156
1661
—
23
18
147
1662
25
108
134
1511
43
176
84
1186
Thyroxine (T4) free [Moles/volume] in Serum or Plasma
14920-3 [3008486]
6.0e-01
1.5e+00
2.5e+00
—
2.6e+00
1.0e+00
7.2e-01
cases:31.76%
controls:20.28%
cases:34.50%
controls:10.46%
cases:12.28%
controls:1.19%
—
—
cases:14.71%
controls:1.31%
cases:25.16%
controls:10.62%
cases:48.03%
controls:31.13%
54
339
116
1333
59
176
112
1506
21
20
150
1662
—
25
22
145
1658
40
172
119
1447
61
424
66
938
Basophils [#/volume] in Blood
26444-0 [3006315]
7.9e-01
1.2e+00
2.0e+00
—
2.8e+00
8.9e-01
1.1e+00
cases:21.18%
controls:10.83%
cases:18.13%
controls:6.30%
cases:9.36%
controls:1.43%
—
—
cases:12.94%
controls:0.89%
cases:16.35%
controls:7.41%
cases:33.86%
controls:14.76%
36
181
134
1491
31
106
140
1576
16
24
155
1658
—
22
15
148
1665
26
120
133
1499
43
201
84
1161
Monocytes [#/volume] in Blood
26484-6 [3001604]
8.0e-01
1.2e+00
1.9e+00
—
2.8e+00
8.9e-01
1.1e+00
cases:21.18%
controls:10.77%
cases:18.13%
controls:6.30%
cases:8.77%
controls:1.43%
—
—
cases:12.94%
controls:0.89%
cases:16.35%
controls:7.41%
cases:33.86%
controls:14.76%
36
180
134
1492
31
106
140
1576
15
24
156
1658
—
22
15
148
1665
26
120
133
1499
43
201
84
1161
CBC W Ordered Manual Differential panel - Blood
57782-5 [40760892]
9.4e-01
1.3e+00
2.3e+00
—
3.0e+00
1.1e+00
1.1e+00
cases:10.59%
controls:4.43%
cases:7.02%
controls:1.96%
cases:4.09%
controls:0.42%
—
—
cases:9.41%
controls:0.54%
cases:6.92%
controls:2.35%
cases:18.11%
controls:7.12%
18
74
152
1598
12
33
159
1649
7
7
164
1675
—
16
9
154
1671
11
38
148
1581
23
97
104
1265
Eosinophils [#/volume] in Blood
26449-9 [3013115]
8.0e-01
1.1e+00
1.8e+00
—
2.7e+00
9.5e-01
1.0e+00
cases:22.35%
controls:11.42%
cases:18.13%
controls:6.60%
cases:9.36%
controls:1.61%
—
—
cases:12.94%
controls:0.95%
cases:17.61%
controls:7.66%
cases:33.86%
controls:15.20%
38
191
132
1481
31
111
140
1571
16
27
155
1655
—
22
16
148
1664
28
124
131
1495
43
207
84
1155
Lymphocytes [#/volume] in Blood
26474-7 [3019198]
7.6e-01
1.1e+00
1.9e+00
—
2.8e+00
8.3e-01
1.1e+00
cases:21.18%
controls:11.18%
cases:17.54%
controls:6.48%
cases:8.77%
controls:1.49%
—
—
cases:12.94%
controls:0.89%
cases:15.72%
controls:7.54%
cases:34.65%
controls:15.20%
36
187
134
1485
30
109
141
1573
15
25
156
1657
—
22
15
148
1665
25
122
134
1497
44
207
83
1155
Urinalysis microscopic panel [#/volume] - Urine by Automated count
50554-5 [3029287]
8.8e-01
1.4e+00
2.5e+00
1.0e+50
2.6e+00
8.7e-01
1.0e+00
cases:15.88%
controls:7.24%
cases:12.87%
controls:3.39%
cases:4.68%
controls:0.42%
cases:4.68%
controls:0.00%
cases:5.88%
controls:0.48%
cases:9.43%
controls:4.20%
cases:22.83%
controls:9.69%
27
121
143
1551
22
57
149
1625
8
7
163
1675
8
0
163
1682
10
8
160
1672
15
68
144
1551
29
132
98
1230
Gastroenterology
10 [38004455]
1.2e+00
1.4e+00
1.6e+00
—
2.2e+00
1.9e+00
1.6e+00
cases:17.65%
controls:5.86%
cases:8.19%
controls:2.20%
cases:3.51%
controls:0.71%
—
—
cases:4.71%
controls:0.54%
cases:12.58%
controls:2.10%
cases:21.26%
controls:5.14%
30
98
140
1574
14
37
157
1645
6
12
165
1670
—
8
9
162
1671
20
34
139
1585
27
70
100
1292
Bilirubin.total [Moles/volume] in Serum or Plasma
14631-6 [3006140]
5.5e-01
1.0e+00
2.5e+00
—
2.2e+00
1.4e+00
1.2e+00
cases:18.24%
controls:11.42%
cases:16.96%
controls:6.78%
cases:12.87%
controls:1.25%
—
—
cases:11.18%
controls:1.37%
cases:22.64%
controls:6.79%
cases:35.43%
controls:14.76%
31
191
139
1481
29
114
142
1568
22
21
149
1661
—
19
23
151
1657
36
110
123
1509
45
201
82
1161
Erythrocyte [DistWidth] in Red Blood Cells
30385-9 [3002385]
3.9e-01
5.7e-01
1.8e+00
3.7e+00
2.0e+00
7.3e-01
2.2e-01
cases:33.53%
controls:25.48%
cases:31.58%
controls:20.75%
cases:25.15%
controls:5.11%
cases:16.37%
controls:0.48%
cases:24.71%
controls:4.40%
cases:35.85%
controls:21.19%
cases:42.52%
controls:37.22%
57
426
113
1246
54
349
117
1333
43
86
128
1596
28
8
143
1674
42
74
128
1606
57
343
102
1276
54
507
73
855
Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1742-6 [3006923]
2.3e-01
6.0e-01
1.5e+00
3.5e+00
1.6e+00
8.6e-01
2.6e-01
cases:40.59%
controls:35.17%
cases:38.60%
controls:25.74%
cases:19.30%
controls:4.88%
cases:9.36%
controls:0.30%
cases:18.82%
controls:4.40%
cases:45.28%
controls:25.94%
cases:56.69%
controls:50.15%
69
588
101
1084
66
433
105
1249
33
82
138
1600
16
5
155
1677
32
74
138
1606
72
420
87
1199
72
683
55
679
Outpatient Hospital
22 [8756]
6.3e-01
1.0e+00
1.8e+00
—
2.2e+00
1.6e+00
8.5e-01
cases:35.88%
controls:22.91%
cases:15.79%
controls:6.42%
cases:4.09%
controls:0.71%
—
—
cases:5.29%
controls:0.60%
cases:20.75%
controls:4.82%
cases:29.13%
controls:14.98%
61
383
109
1289
27
108
144
1574
7
12
164
1670
—
9
10
161
1670
33
78
126
1541
37
204
90
1158
Glucose [Moles/volume] in Serum or Plasma
14749-6 [3013826]
5.5e-01
1.0e+00
2.3e+00
—
2.4e+00
1.5e+00
8.4e-01
cases:20.59%
controls:13.04%
cases:18.13%
controls:7.37%
cases:9.36%
controls:1.01%
—
—
cases:10.00%
controls:0.95%
cases:23.27%
controls:6.55%
cases:33.07%
controls:17.62%
35
218
135
1454
31
124
140
1558
16
17
155
1665
—
17
16
153
1664
37
106
122
1513
42
240
85
1122
Neurology
13 [38004458]
9.2e-01
1.1e+00
1.9e+00
—
1.8e+00
1.2e+00
1.2e+00
cases:22.35%
controls:10.29%
cases:10.53%
controls:3.92%
cases:4.68%
controls:0.71%
—
—
cases:4.12%
controls:0.71%
cases:11.95%
controls:4.08%
cases:25.20%
controls:9.18%
38
172
132
1500
18
66
153
1616
8
12
163
1670
—
7
12
163
1668
19
66
140
1553
32
125
95
1237
Emergency Room Visit
ER [9203]
9.5e-01
1.1e+00
2.2e+00
1.0e+50
1.5e+00
1.3e+00
9.0e-01
cases:53.53%
controls:30.80%
cases:27.49%
controls:10.76%
cases:14.04%
controls:1.78%
cases:16.37%
controls:0.00%
cases:5.88%
controls:1.31%
cases:27.67%
controls:9.57%
cases:45.67%
controls:25.40%
91
515
79
1157
47
181
124
1501
24
30
147
1652
28
0
143
1682
10
22
160
1658
44
155
115
1464
58
346
69
1016
Bacteria [#/volume] in Urine by Automated count
51480-2 [3031040]
7.3e-01
1.1e+00
1.9e+00
1.0e+50
2.4e+00
1.0e+00
8.9e-01
cases:26.47%
controls:14.77%
cases:21.05%
controls:8.38%
cases:7.60%
controls:1.25%
cases:7.02%
controls:0.00%
cases:11.76%
controls:1.19%
cases:20.13%
controls:8.28%
cases:37.01%
controls:19.38%
45
247
125
1425
36
141
135
1541
13
21
158
1661
12
0
159
1682
20
20
150
1660
32
134
127
1485
47
264
80
1098
Physical Medicine And Rehabilitation
25 [38004468]
1.3e+00
1.4e+00
—
—
2.7e+00
1.5e+00
1.1e+00
cases:20.59%
controls:6.70%
cases:7.60%
controls:2.08%
—
—
—
—
cases:4.12%
controls:0.30%
cases:8.81%
controls:2.04%
cases:21.26%
controls:8.52%
35
112
135
1560
13
35
158
1647
—
—
7
5
163
1675
14
33
145
1586
27
116
100
1246
Laboratory Visit
OMOP4822461 [32036]
2.2e-01
4.9e-01
1.7e+00
3.8e+00
1.7e+00
6.1e-01
1.1e-01
cases:50.59%
controls:45.16%
cases:54.39%
controls:42.21%
cases:45.03%
controls:12.96%
cases:25.15%
controls:0.71%
cases:43.53%
controls:12.02%
cases:59.75%
controls:44.60%
cases:64.57%
controls:62.11%
86
755
84
917
93
710
78
972
77
218
94
1464
43
12
128
1670
74
202
96
1478
95
722
64
897
82
846
45
516
Neutrophils/Leukocytes in Blood
26511-6 [3018010]
5.3e-01
1.1e+00
1.9e+00
—
2.6e+00
1.0e+00
1.1e+00
cases:16.47%
controls:10.41%
cases:15.79%
controls:5.89%
cases:8.19%
controls:1.31%
—
—
cases:12.35%
controls:1.01%
cases:16.35%
controls:6.73%
cases:32.28%
controls:13.22%
28
174
142
1498
27
99
144
1583
14
22
157
1660
—
21
17
149
1663
26
109
133
1510
41
180
86
1182
Erythrocyte sedimentation rate [Velocity] in Red Blood Cells by Westergren method
4537-7 [3013707]
5.4e-01
1.2e+00
1.9e+00
1.0e+50
2.7e+00
1.1e+00
6.9e-01
cases:29.41%
controls:19.56%
cases:25.73%
controls:9.87%
cases:9.36%
controls:1.55%
cases:2.92%
controls:0.00%
cases:12.35%
controls:0.89%
cases:25.79%
controls:10.19%
cases:41.73%
controls:26.51%
50
327
120
1345
44
166
127
1516
16
26
155
1656
5
0
166
1682
21
15
149
1665
41
165
118
1454
53
361
74
1001
Erythrocytes [Presence] in Urine by Automated
53292-9 [3041096]
1.0e+00
1.3e+00
2.7e+00
1.0e+50
2.5e+00
9.3e-01
6.4e-01
cases:13.53%
controls:5.32%
cases:9.36%
controls:2.68%
cases:5.85%
controls:0.42%
cases:3.51%
controls:0.00%
cases:5.29%
controls:0.48%
cases:8.18%
controls:3.40%
cases:16.54%
controls:9.47%
23
89
147
1583
16
45
155
1637
10
7
161
1675
6
0
165
1682
9
8
161
1672
13
55
146
1564
21
129
106
1233
Urinalysis macro (dipstick) panel - Urine
24357-6 [3037467]
7.7e-01
1.0e+00
1.8e+00
1.0e+50
2.2e+00
9.8e-01
6.9e-01
cases:30.00%
controls:16.63%
cases:21.05%
controls:8.86%
cases:7.60%
controls:1.37%
cases:7.60%
controls:0.00%
cases:10.00%
controls:1.19%
cases:20.13%
controls:8.65%
cases:35.43%
controls:21.51%
51
278
119
1394
36
149
135
1533
13
23
158
1659
13
0
158
1682
17
20
153
1660
32
140
127
1479
45
293
82
1069
buprenorphine; parenteral, sublingual, transdermal
N02AE01 [21604287]
1.8e+00
2.2e+00
—
—
2.3e+00
1.9e+00
1.6e+00
cases:7.65%
controls:1.38%
cases:7.02%
controls:0.83%
—
—
—
—
cases:2.94%
controls:0.30%
cases:8.81%
controls:1.42%
cases:11.81%
controls:2.72%
13
23
157
1649
12
14
159
1668
—
—
5
5
165
1675
14
23
145
1596
15
37
112
1325
Type 2 diabetes mellitus, without complications
E11.9 [45561952]
9.2e-01
7.3e-01
2.2e+00
—
2.6e+00
1.5e+00
1.2e+00
cases:10.00%
controls:4.25%
cases:4.68%
controls:2.32%
cases:4.09%
controls:0.48%
—
—
cases:4.71%
controls:0.36%
cases:11.32%
controls:2.90%
cases:15.75%
controls:5.43%
17
71
153
1601
8
39
163
1643
7
8
164
1674
—
8
6
162
1674
18
47
141
1572
20
74
107
1288
Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma
6768-6 [3035995]
5.3e-01
9.5e-01
2.1e+00
—
2.2e+00
1.2e+00
9.3e-01
cases:29.41%
controls:19.74%
cases:28.07%
controls:13.08%
cases:16.96%
controls:2.44%
—
—
cases:16.47%
controls:2.20%
cases:33.96%
controls:13.09%
cases:48.82%
controls:27.31%
50
330
120
1342
48
220
123
1462
29
41
142
1641
—
28
37
142
1643
54
212
105
1407
62
372
65
990
Psychiatry
26 [38004469]
1.1e+00
1.2e+00
—
—
2.1e+00
1.5e+00
1.5e+00
cases:15.29%
controls:5.74%
cases:9.94%
controls:3.27%
—
—
—
—
cases:7.65%
controls:1.01%
cases:12.58%
controls:3.09%
cases:21.26%
controls:5.80%
26
96
144
1576
17
55
154
1627
—
—
13
17
157
1663
20
50
139
1569
27
79
100
1283
Differential panel, method unspecified - Blood
69738-3 [42870588]
8.9e-01
1.3e+00
1.5e+00
—
2.5e+00
1.0e+00
1.5e+00
cases:14.12%
controls:6.34%
cases:12.87%
controls:3.98%
cases:4.68%
controls:1.07%
—
—
cases:9.41%
controls:0.83%
cases:11.95%
controls:4.76%
cases:28.35%
controls:8.15%
24
106
146
1566
22
67
149
1615
8
18
163
1664
—
16
14
154
1666
19
77
140
1542
36
111
91
1251
Triiodothyronine (T3) Free [Moles/volume] in Serum or Plasma
14928-6 [3026989]
9.7e-01
2.0e+00
—
—
1.0e+50
2.6e+00
2.6e+00
cases:2.94%
controls:1.14%
cases:4.09%
controls:0.59%
—
—
—
—
cases:2.94%
controls:0.00%
cases:6.29%
controls:0.49%
cases:11.81%
controls:1.03%
5
19
165
1653
7
10
164
1672
—
—
5
0
165
1680
10
8
149
1611
15
14
112
1348
MCHC [Entitic Mass/volume] in Red Blood Cells
28540-3 [3003338]
2.1e-01
5.4e-01
1.6e+00
3.8e+00
1.7e+00
4.0e-01
-1.5e-01
cases:35.29%
controls:30.74%
cases:33.33%
controls:22.59%
cases:21.05%
controls:5.11%
cases:11.70%
controls:0.30%
cases:18.82%
controls:4.17%
cases:32.08%
controls:24.03%
cases:39.37%
controls:43.10%
60
514
110
1158
57
380
114
1302
36
86
135
1596
20
5
151
1677
32
70
138
1610
51
389
108
1230
50
587
77
775
Normoblasts [#/volume] in Blood
715-3 [3021589]
7.5e-01
8.6e-01
1.6e+00
—
2.1e+00
8.9e-01
7.5e-01
cases:17.06%
controls:8.85%
cases:15.20%
controls:7.07%
cases:9.36%
controls:1.96%
—
—
cases:10.00%
controls:1.37%
cases:17.61%
controls:8.09%
cases:25.98%
controls:14.17%
29
148
141
1524
26
119
145
1563
16
33
155
1649
—
17
23
153
1657
28
131
131
1488
33
193
94
1169
Creatine kinase [Enzymatic activity/volume] in Serum or Plasma
2157-6 [3007220]
1.0e+00
1.5e+00
2.3e+00
—
2.7e+00
1.7e+00
6.7e-01
cases:12.35%
controls:4.84%
cases:9.36%
controls:2.20%
cases:2.92%
controls:0.30%
—
—
cases:4.12%
controls:0.30%
cases:10.06%
controls:1.98%
cases:11.81%
controls:6.39%
21
81
149
1591
16
37
155
1645
5
5
166
1677
—
7
5
163
1675
16
32
143
1587
15
87
112
1275
furosemide; oral, parenteral
C03CA01 [21601518]
1.1e+00
1.4e+00
9.7e-01
—
1.7e+00
1.4e+00
1.3e+00
cases:13.53%
controls:4.90%
cases:14.62%
controls:3.86%
cases:2.92%
controls:1.13%
—
—
cases:7.06%
controls:1.43%
cases:15.09%
controls:4.26%
cases:20.47%
controls:6.61%
23
82
147
1590
25
65
146
1617
5
19
166
1663
—
12
24
158
1656
24
69
135
1550
26
90
101
1272
IgM [Mass/volume] in Serum or Plasma
2472-9 [3028026]
—
1.9e+00
—
—
—
2.8e+00
2.2e+00
—
—
cases:4.09%
controls:0.65%
—
—
—
—
—
—
cases:5.03%
controls:0.31%
cases:7.87%
controls:0.95%
—
7
11
164
1671
—
—
—
8
5
151
1614
10
13
117
1349
25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Moles/volume] in Serum or Plasma
68438-1 [40771025]
9.2e-01
9.8e-01
2.1e+00
—
—
1.6e+00
1.3e+00
cases:16.47%
controls:7.30%
cases:12.87%
controls:5.23%
cases:4.09%
controls:0.54%
—
—
—
—
cases:17.61%
controls:4.14%
cases:36.22%
controls:13.51%
28
122
142
1550
22
88
149
1594
7
9
164
1673
—
—
28
67
131
1552
46
184
81
1178
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Blood
47598-8 [3048816]
1.1e+00
2.6e+00
—
—
—
2.2e+00
2.0e+00
cases:4.12%
controls:1.44%
cases:7.60%
controls:0.59%
—
—
—
—
—
—
cases:4.40%
controls:0.49%
cases:9.45%
controls:1.40%
7
24
163
1648
13
10
158
1672
—
—
—
7
8
152
1611
12
19
115
1343
Bacteria identified in Urine by Culture
630-4 [3026008]
8.8e-01
8.9e-01
2.2e+00
—
2.8e+00
7.5e-01
9.4e-01
cases:12.94%
controls:5.80%
cases:7.60%
controls:3.27%
cases:4.09%
controls:0.48%
—
—
cases:4.71%
controls:0.30%
cases:6.92%
controls:3.40%
cases:18.90%
controls:8.37%
22
97
148
1575
13
55
158
1627
7
8
164
1674
—
8
5
162
1675
11
55
148
1564
24
114
103
1248
Emergency Medicine
93 [38004510]
8.0e-01
1.0e+00
2.2e+00
—
1.7e+00
1.0e+00
6.2e-01
cases:27.65%
controls:14.59%
cases:20.47%
controls:8.32%
cases:11.11%
controls:1.31%
—
—
cases:5.88%
controls:1.13%
cases:21.38%
controls:9.02%
cases:37.80%
controls:24.60%
47
244
123
1428
35
140
136
1542
19
22
152
1660
—
10
19
160
1661
34
146
125
1473
48
335
79
1027
General Practice
1 [38004446]
7.6e-01
1.4e+00
1.4e+00
1.0e+50
2.5e+00
8.9e-01
1.1e+00
cases:23.53%
controls:12.56%
cases:15.79%
controls:4.22%
cases:3.51%
controls:0.89%
cases:5.26%
controls:0.00%
cases:7.65%
controls:0.65%
cases:13.84%
controls:6.18%
cases:33.86%
controls:13.95%
40
210
130
1462
27
71
144
1611
6
15
165
1667
9
0
162
1682
13
11
157
1669
22
100
137
1519
43
190
84
1172
calcium (different salts in combination); oral
A12AA20 [21600872]
9.8e-01
1.2e+00
4.4e-01
—
1.9e+00
1.4e+00
1.4e+00
cases:18.82%
controls:8.01%
cases:18.13%
controls:6.42%
cases:2.92%
controls:1.90%
—
—
cases:9.41%
controls:1.55%
cases:20.13%
controls:6.11%
cases:25.98%
controls:8.22%
32
134
138
1538
31
108
140
1574
5
32
166
1650
—
16
26
154
1654
32
99
127
1520
33
112
94
1250
Amylase [Enzymatic activity/volume] in Serum or Plasma
1798-8 [3016771]
5.6e-01
1.5e+00
—
—
2.6e+00
1.6e+00
1.1e+00
cases:10.59%
controls:6.34%
cases:11.11%
controls:2.68%
—
—
—
—
cases:5.88%
controls:0.48%
cases:12.58%
controls:2.78%
cases:20.47%
controls:8.22%
18
106
152
1566
19
45
152
1637
—
—
10
8
160
1672
20
45
139
1574
26
112
101
1250
Microorganisms panel - Urine sediment
58435-9 [40761536]
1.5e+00
1.9e+00
—
—
—
1.9e+00
1.5e+00
cases:5.88%
controls:1.38%
cases:4.09%
controls:0.65%
—
—
—
—
—
—
cases:5.66%
controls:0.93%
cases:8.66%
controls:2.06%
10
23
160
1649
7
11
164
1671
—
—
—
9
15
150
1604
11
28
116
1334
Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma
33762-6 [3029187]
8.5e-01
1.2e+00
—
—
3.0e+00
1.4e+00
1.1e+00
cases:11.18%
controls:5.08%
cases:9.36%
controls:2.91%
—
—
—
—
cases:5.88%
controls:0.30%
cases:11.32%
controls:3.15%
cases:19.69%
controls:7.71%
19
85
151
1587
16
49
155
1633
—
—
10
5
160
1675
18
51
141
1568
25
105
102
1257
metoclopramide; oral, parenteral, rectal
A03FA01 [21600484]
1.3e+00
1.6e+00
—
—
—
2.0e+00
1.6e+00
cases:12.35%
controls:3.71%
cases:5.85%
controls:1.25%
—
—
—
—
—
—
cases:7.55%
controls:1.05%
cases:14.96%
controls:3.30%
21
62
149
1610
10
21
161
1661
—
—
—
12
17
147
1602
19
45
108
1317
Erythrocytes [#/volume] in Urine
30391-7 [3002582]
6.7e-01
1.6e+00
—
1.0e+50
2.8e+00
1.0e+00
1.2e+00
cases:11.18%
controls:6.04%
cases:12.28%
controls:2.85%
—
—
cases:4.09%
controls:0.00%
cases:6.47%
controls:0.42%
cases:10.06%
controls:3.95%
cases:24.41%
controls:9.03%
19
101
151
1571
21
48
150
1634
—
7
0
164
1682
11
7
159
1673
16
64
143
1555
31
123
96
1239
Other and unspecified abdominal pain
R10.4 [45568113]
7.6e-01
1.4e+00
2.5e+00
—
—
1.6e+00
1.1e+00
cases:11.76%
controls:5.86%
cases:7.02%
controls:1.90%
cases:3.51%
controls:0.30%
—
—
—
—
cases:8.18%
controls:1.73%
cases:17.32%
controls:6.83%
20
98
150
1574
12
32
159
1650
6
5
165
1677
—
—
13
28
146
1591
22
93
105
1269
Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma
2324-2 [3026910]
2.4e-02
9.4e-01
2.1e+00
—
2.1e+00
1.3e+00
5.2e-01
cases:16.47%
controls:16.15%
cases:16.96%
controls:7.37%
cases:7.60%
controls:0.95%
—
—
cases:7.06%
controls:0.89%
cases:20.75%
controls:6.86%
cases:33.86%
controls:23.27%
28
270
142
1402
29
124
142
1558
13
16
158
1666
—
12
15
158
1665
33
111
126
1508
43
317
84
1045
Asthma, unspecified
J45.9 [45562456]
1.5e+00
1.7e+00
—
1.0e+50
—
1.9e+00
1.4e+00
cases:12.94%
controls:3.17%
cases:7.60%
controls:1.55%
—
—
cases:7.60%
controls:0.00%
—
—
cases:8.18%
controls:1.30%
cases:11.81%
controls:3.23%
22
53
148
1619
13
26
158
1656
—
13
0
158
1682
—
13
21
146
1598
15
44
112
1318
salmeterol and fluticasone
R03AK06 [21603280]
1.4e+00
1.8e+00
2.1e+00
—
—
1.7e+00
1.5e+00
cases:9.41%
controls:2.39%
cases:7.60%
controls:1.37%
cases:2.92%
controls:0.36%
—
—
—
—
cases:6.29%
controls:1.24%
cases:9.45%
controls:2.28%
16
40
154
1632
13
23
158
1659
5
6
166
1676
—
—
10
20
149
1599
12
31
115
1331
Thyrotropin [Units/volume] in Serum or Plasma
3016-3 [3009201]
4.4e-01
1.1e+00
2.0e+00
—
2.4e+00
8.7e-01
4.5e-01
cases:36.47%
controls:26.97%
cases:38.01%
controls:16.59%
cases:13.45%
controls:1.96%
—
—
cases:16.47%
controls:1.85%
cases:30.19%
controls:15.38%
cases:51.18%
controls:40.16%
62
451
108
1221
65
279
106
1403
23
33
148
1649
—
28
31
142
1649
48
249
111
1370
65
547
62
815
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]
5.2e-01
8.9e-01
2.0e+00
—
2.4e+00
1.0e+00
5.9e-01
cases:41.76%
controls:29.90%
cases:38.60%
controls:20.45%
cases:24.56%
controls:4.10%
—
—
cases:27.65%
controls:3.27%
cases:42.77%
controls:21.62%
cases:57.48%
controls:42.80%
71
500
99
1172
66
344
105
1338
42
69
129
1613
—
47
55
123
1625
68
350
91
1269
73
583
54
779
Neutrophils [#/volume] in Blood by Automated count
751-8 [3013650]
5.4e-01
9.4e-01
1.7e+00
—
2.6e+00
7.1e-01
1.1e+00
cases:20.59%
controls:13.16%
cases:18.13%
controls:7.97%
cases:11.11%
controls:2.26%
—
—
cases:17.06%
controls:1.55%
cases:16.98%
controls:9.14%
cases:38.58%
controls:16.89%
35
220
135
1452
31
134
140
1548
19
38
152
1644
—
29
26
141
1654
27
148
132
1471
49
230
78
1132
Emergency Room and Inpatient Visit
ERIP [262]
1.1e+00
7.5e-01
2.2e+00
1.0e+50
2.2e+00
6.2e-01
9.2e-01
cases:12.35%
controls:4.67%
cases:5.85%
controls:2.85%
cases:3.51%
controls:0.42%
cases:11.70%
controls:0.00%
cases:3.53%
controls:0.42%
cases:6.92%
controls:3.83%
cases:23.62%
controls:10.94%
21
78
149
1594
10
48
161
1634
6
7
165
1675
20
0
151
1682
6
7
164
1673
11
62
148
1557
30
149
97
1213
epinephrine
S01EA01 [21603673]
1.8e+00
1.8e+00
—
—
—
2.4e+00
2.1e+00
cases:4.12%
controls:0.72%
cases:2.92%
controls:0.48%
—
—
—
—
—
—
cases:3.77%
controls:0.37%
cases:5.51%
controls:0.73%
7
12
163
1660
5
8
166
1674
—
—
—
6
6
153
1613
7
10
120
1352
epinephrine; parenteral
C01CA24 [21600303]
1.8e+00
1.8e+00
—
—
—
2.4e+00
2.1e+00
cases:4.12%
controls:0.72%
cases:2.92%
controls:0.48%
—
—
—
—
—
—
cases:3.77%
controls:0.37%
cases:5.51%
controls:0.73%
7
12
163
1660
5
8
166
1674
—
—
—
6
6
153
1613
7
10
120
1352
Cardiology
6 [38004451]
6.9e-01
1.1e+00
1.9e+00
1.0e+50
2.5e+00
1.3e+00
1.2e+00
cases:17.65%
controls:9.69%
cases:12.28%
controls:4.34%
cases:3.51%
controls:0.54%
cases:2.92%
controls:0.00%
cases:5.29%
controls:0.48%
cases:14.47%
controls:4.39%
cases:25.20%
controls:8.81%
30
162
140
1510
21
73
150
1609
6
9
165
1673
5
0
166
1682
9
8
161
1672
23
71
136
1548
32
120
95
1242
Atrial fibrillation and flutter
I48 [45596206]
1.0e+00
1.2e+00
2.0e+00
—
1.8e+00
9.6e-01
4.0e-01
cases:11.76%
controls:4.67%
cases:7.60%
controls:2.38%
cases:4.68%
controls:0.65%
—
—
cases:4.71%
controls:0.77%
cases:6.92%
controls:2.78%
cases:7.87%
controls:5.43%
20
78
150
1594
13
40
158
1642
8
11
163
1671
—
8
13
162
1667
11
45
148
1574
10
74
117
1288
Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1920-8 [3013721]
7.5e-01
1.4e+00
2.8e+00
—
1.6e+00
1.6e+00
7.9e-01
cases:14.12%
controls:7.24%
cases:12.87%
controls:3.39%
cases:4.68%
controls:0.30%
—
—
cases:2.94%
controls:0.60%
cases:15.09%
controls:3.34%
cases:19.69%
controls:9.99%
24
121
146
1551
22
57
149
1625
8
5
163
1677
—
5
10
165
1670
24
54
135
1565
25
136
102
1226
Chest pain, unspecified
R07.4 [45558450]
1.2e+00
1.6e+00
—
—
—
1.8e+00
1.2e+00
cases:11.18%
controls:3.83%
cases:5.85%
controls:1.19%
—
—
—
—
—
—
cases:6.29%
controls:1.11%
cases:11.81%
controls:3.96%
19
64
151
1608
10
20
161
1662
—
—
—
10
18
149
1601
15
54
112
1308
oxycodone; oral, parenteral
N02AA05 [21604260]
1.8e+00
2.1e+00
—
—
2.3e+00
1.4e+00
1.8e+00
cases:7.06%
controls:1.26%
cases:6.43%
controls:0.83%
—
—
—
—
cases:2.94%
controls:0.30%
cases:5.66%
controls:1.42%
cases:11.81%
controls:2.13%
12
21
158
1651
11
14
160
1668
—
—
5
5
165
1675
9
23
150
1596
15
29
112
1333
Leukocyte esterase [Presence] in Urine by Automated test strip
60026-2 [40763086]
7.2e-01
9.6e-01
2.1e+00
1.0e+50
2.6e+00
7.9e-01
3.9e-01
cases:15.88%
controls:8.43%
cases:11.70%
controls:4.82%
cases:6.43%
controls:0.83%
cases:5.26%
controls:0.00%
cases:7.65%
controls:0.60%
cases:11.95%
controls:5.81%
cases:20.47%
controls:14.83%
27
141
143
1531
20
81
151
1601
11
14
160
1668
9
0
162
1682
13
10
157
1670
19
94
140
1525
26
202
101
1160
Ferritin [Mass/volume] in Serum or Plasma
2276-4 [3001122]
7.2e-01
1.1e+00
1.6e+00
—
2.3e+00
1.2e+00
9.5e-01
cases:15.29%
controls:8.07%
cases:12.87%
controls:4.64%
cases:4.09%
controls:0.83%
—
—
cases:5.29%
controls:0.54%
cases:13.21%
controls:4.39%
cases:33.86%
controls:16.52%
26
135
144
1537
22
78
149
1604
7
14
164
1668
—
9
9
161
1671
21
71
138
1548
43
225
84
1137
Malaise and fatigue
R53 [45553741]
1.5e+00
1.8e+00
—
1.0e+50
—
2.2e+00
9.2e-01
cases:10.00%
controls:2.45%
cases:8.19%
controls:1.49%
—
—
cases:5.85%
controls:0.00%
—
—
cases:9.43%
controls:1.11%
cases:12.60%
controls:5.43%
17
41
153
1631
14
25
157
1657
—
10
0
161
1682
—
15
18
144
1601
16
74
111
1288
Glucose [Presence] in Urine by Test strip
25428-4 [3009261]
6.0e-01
7.4e-01
2.0e+00
1.0e+50
2.7e+00
8.4e-01
3.2e-01
cases:16.47%
controls:9.75%
cases:12.87%
controls:6.60%
cases:6.43%
controls:0.95%
cases:6.43%
controls:0.00%
cases:9.41%
controls:0.71%
cases:15.09%
controls:7.10%
cases:23.62%
controls:18.28%
28
163
142
1509
22
111
149
1571
11
16
160
1666
11
0
160
1682
16
12
154
1668
24
115
135
1504
30
249
97
1113
Thorax X-ray examination
GD1AA [2001303617]
1.1e+00
1.1e+00
—
1.0e+50
—
1.6e+00
1.7e+00
cases:20.59%
controls:8.31%
cases:10.53%
controls:3.69%
—
—
cases:7.02%
controls:0.00%
—
—
cases:14.47%
controls:3.34%
cases:31.50%
controls:7.71%
35
139
135
1533
18
62
153
1620
—
12
0
159
1682
—
23
54
136
1565
40
105
87
1257
Ketones [Presence] in Urine by Test strip
2514-8 [3035350]
6.1e-01
7.5e-01
2.0e+00
1.0e+50
2.6e+00
8.9e-01
3.2e-01
cases:16.47%
controls:9.69%
cases:12.87%
controls:6.54%
cases:6.43%
controls:0.95%
cases:6.43%
controls:0.00%
cases:8.82%
controls:0.71%
cases:15.72%
controls:7.10%
cases:23.62%
controls:18.36%
28
162
142
1510
22
110
149
1572
11
16
160
1666
11
0
160
1682
15
12
155
1668
25
115
134
1504
30
250
97
1112
tiotropium bromide; inhalant
R03BB04 [21603296]
1.7e+00
2.1e+00
—
—
1.7e+00
1.6e+00
1.4e+00
cases:8.24%
controls:1.56%
cases:7.02%
controls:0.95%
—
—
—
—
cases:2.94%
controls:0.54%
cases:6.29%
controls:1.30%
cases:7.09%
controls:1.91%
14
26
156
1646
12
16
159
1666
—
—
5
9
165
1671
10
21
149
1598
9
26
118
1336
Nitrite [Presence] in Urine by Test strip
5802-4 [3021601]
5.7e-01
6.8e-01
1.9e+00
1.0e+50
2.6e+00
8.8e-01
3.3e-01
cases:15.88%
controls:9.69%
cases:12.28%
controls:6.60%
cases:5.85%
controls:0.89%
cases:6.43%
controls:0.00%
cases:8.82%
controls:0.71%
cases:15.72%
controls:7.16%
cases:23.62%
controls:18.21%
27
162
143
1510
21
111
150
1571
10
15
161
1667
11
0
160
1682
15
12
155
1668
25
116
134
1503
30
248
97
1114
pregabalin; oral
N02BF02 [955152]
1.2e+00
1.3e+00
1.8e+00
—
1.6e+00
1.6e+00
1.3e+00
cases:11.76%
controls:4.01%
cases:6.43%
controls:1.78%
cases:2.92%
controls:0.48%
—
—
cases:3.53%
controls:0.71%
cases:8.18%
controls:1.73%
cases:12.60%
controls:3.82%
20
67
150
1605
11
30
160
1652
5
8
166
1674
—
6
12
164
1668
13
28
146
1591
16
52
111
1310
Supplier / Service Provider
OMOP5117446 [33004]
-4.6e-01
-4.3e-01
—
—
—
2.1e+00
3.1e+00
cases:18.82%
controls:26.79%
cases:6.43%
controls:9.57%
—
—
—
—
—
—
cases:6.92%
controls:0.86%
cases:17.32%
controls:0.95%
32
448
138
1224
11
161
160
1521
—
—
—
11
14
148
1605
22
13
105
1349
Leukocytes [#/volume] in Urine
30405-5 [3018095]
7.2e-01
1.5e+00
—
1.0e+50
2.5e+00
9.0e-01
1.1e+00
cases:12.94%
controls:6.76%
cases:14.04%
controls:3.39%
—
—
cases:4.09%
controls:0.00%
cases:6.47%
controls:0.54%
cases:10.69%
controls:4.63%
cases:25.98%
controls:10.43%
22
113
148
1559
24
57
147
1625
—
7
0
164
1682
11
9
159
1671
17
75
142
1544
33
142
94
1220
Case Management Agency
251B00000X [38004193]
3.0e-01
5.1e-01
9.5e-01
3.3e+00
9.6e-01
6.1e-01
1.1e-01
cases:73.53%
controls:67.34%
cases:69.59%
controls:57.85%
cases:45.03%
controls:24.14%
cases:30.41%
controls:1.66%
cases:45.29%
controls:24.05%
cases:73.58%
controls:60.28%
cases:80.31%
controls:78.56%
125
1126
45
546
119
973
52
709
77
406
94
1276
52
28
119
1654
77
404
93
1276
117
976
42
643
102
1070
25
292
Casts [#/volume] in Urine by Automated count
51483-6 [3030467]
8.2e-01
1.3e+00
—
1.0e+50
2.7e+00
9.7e-01
1.1e+00
cases:11.18%
controls:5.26%
cases:8.77%
controls:2.62%
—
—
cases:3.51%
controls:0.00%
cases:5.29%
controls:0.36%
cases:8.18%
controls:3.27%
cases:18.90%
controls:7.27%
19
88
151
1584
15
44
156
1638
—
6
0
165
1682
9
6
161
1674
13
53
146
1566
24
99
103
1263
Bacteria [Presence] in Urine
87829-8 [36304419]
7.8e-01
1.5e+00
—
1.0e+50
2.6e+00
1.1e+00
1.0e+00
cases:10.00%
controls:4.84%
cases:8.77%
controls:2.14%
—
—
cases:3.51%
controls:0.00%
cases:5.29%
controls:0.42%
cases:8.18%
controls:2.90%
cases:17.32%
controls:6.98%
17
81
153
1591
15
36
156
1646
—
6
0
165
1682
9
7
161
1673
13
47
146
1572
22
95
105
1267
testosterone; oral, parenteral, rectal, sublingual, transdermal
G03BA03 [21602510]
—
—
—
—
1.0e+50
2.8e+00
2.3e+00
—
—
—
—
—
—
—
—
cases:3.53%
controls:0.00%
cases:5.03%
controls:0.31%
cases:4.72%
controls:0.51%
—
—
—
—
6
0
164
1680
8
5
151
1614
6
7
121
1355
Nuclear Ab [Titer] in Serum
29953-7 [3037522]
8.4e-01
1.7e+00
—
—
—
1.9e+00
1.4e+00
cases:5.88%
controls:2.63%
cases:5.26%
controls:1.01%
—
—
—
—
—
—
cases:4.40%
controls:0.68%
cases:11.02%
controls:2.86%
10
44
160
1628
9
17
162
1665
—
—
—
7
11
152
1608
14
39
113
1323
levothyroxine sodium; oral, parenteral
H03AA01 [21602754]
9.5e-01
9.8e-01
1.2e+00
—
9.0e-01
9.8e-01
8.9e-01
cases:18.82%
controls:8.19%
cases:18.71%
controls:7.97%
cases:7.60%
controls:2.38%
—
—
cases:6.47%
controls:2.74%
cases:19.50%
controls:8.34%
cases:22.83%
controls:10.87%
32
137
138
1535
32
134
139
1548
13
40
158
1642
—
11
46
159
1634
31
135
128
1484
29
148
98
1214
Low back pain
M54.5 [45553207]
9.7e-01
1.7e+00
—
—
—
1.3e+00
9.6e-01
cases:14.12%
controls:5.86%
cases:10.53%
controls:2.02%
—
—
—
—
—
—
cases:6.92%
controls:1.91%
cases:16.54%
controls:7.05%
24
98
146
1574
18
34
153
1648
—
—
—
11
31
148
1588
21
96
106
1266
Transferrin receptor.soluble [Mass/volume] in Serum or Plasma
30248-9 [3015399]
7.7e-01
1.5e+00
1.9e+00
—
2.3e+00
1.2e+00
1.2e+00
cases:8.24%
controls:4.01%
cases:7.60%
controls:1.84%
cases:3.51%
controls:0.54%
—
—
cases:3.53%
controls:0.36%
cases:6.92%
controls:2.10%
cases:20.47%
controls:7.27%
14
67
156
1605
13
31
158
1651
6
9
165
1673
—
6
6
164
1674
11
34
148
1585
26
99
101
1263
Magnesium [Moles/volume] in Serum or Plasma
2601-3 [3012095]
1.2e+00
1.6e+00
—
—
—
1.3e+00
2.0e+00
cases:7.65%
controls:2.33%
cases:5.85%
controls:1.19%
—
—
—
—
—
—
cases:4.40%
controls:1.30%
cases:16.54%
controls:2.64%
13
39
157
1633
10
20
161
1662
—
—
—
7
21
152
1598
21
36
106
1326
Hemoglobin A1c/Hemoglobin.total in Blood
4548-4 [3004410]
4.2e-01
7.5e-01
1.5e+00
—
1.8e+00
8.2e-01
4.6e-01
cases:35.29%
controls:26.32%
cases:29.82%
controls:16.71%
cases:9.36%
controls:2.32%
—
—
cases:10.00%
controls:1.79%
cases:31.45%
controls:16.74%
cases:49.61%
controls:38.33%
60
440
110
1232
51
281
120
1401
16
39
155
1643
—
17
30
153
1650
50
271
109
1348
63
522
64
840
IgG [Mass/volume] in Serum or Plasma
2465-3 [3005719]
7.3e-01
1.4e+00
—
—
—
2.7e+00
2.2e+00
cases:4.12%
controls:2.03%
cases:4.09%
controls:1.01%
—
—
—
—
—
—
cases:8.18%
controls:0.62%
cases:13.39%
controls:1.69%
7
34
163
1638
7
17
164
1665
—
—
—
13
10
146
1609
17
23
110
1339
IgA [Mass/volume] in Serum or Plasma
2458-8 [3007164]
3.7e-01
1.4e+00
-1.0e+50
—
—
2.0e+00
1.4e+00
cases:5.88%
controls:4.13%
cases:6.43%
controls:1.66%
cases:0.00%
controls:0.30%
—
—
—
—
cases:9.43%
controls:1.36%
cases:14.96%
controls:4.11%
10
69
160
1603
11
28
160
1654
0
5
171
1677
—
—
15
22
144
1597
19
56
108
1306
General anesthesia, balanced
WX408 [2001310808]
3.2e-01
—
—
—
—
2.5e+00
2.3e+00
cases:4.71%
controls:3.47%
—
—
—
—
—
—
—
—
cases:5.66%
controls:0.49%
cases:11.81%
controls:1.32%
8
58
162
1614
—
—
—
—
9
8
150
1611
15
18
112
1344
Prothrombin time (PT) actual/Normal
5894-1 [3033658]
3.6e-01
1.2e+00
—
—
2.5e+00
1.2e+00
9.9e-01
cases:7.65%
controls:5.44%
cases:8.19%
controls:2.68%
—
—
—
—
cases:3.53%
controls:0.30%
cases:7.55%
controls:2.47%
cases:14.17%
controls:5.80%
13
91
157
1581
14
45
157
1637
—
—
6
5
164
1675
12
40
147
1579
18
79
109
1283
Pharmacy visit
OMOP4822462 [581458]
2.5e-01
6.3e-01
1.1e+00
2.1e+00
1.4e+00
3.6e-01
2.5e-01
cases:91.18%
controls:88.94%
cases:88.89%
controls:81.03%
cases:70.18%
controls:44.77%
cases:11.70%
controls:1.55%
cases:76.47%
controls:44.46%
cases:86.16%
controls:81.28%
cases:94.49%
controls:93.02%
155
1487
15
185
152
1363
19
319
120
753
51
929
20
26
151
1656
130
747
40
933
137
1316
22
303
120
1267
7
95
Osmolality of Urine
2695-5 [3026782]
1.3e+00
2.0e+00
—
1.0e+50
—
1.2e+00
1.3e+00
cases:12.35%
controls:3.77%
cases:11.70%
controls:1.78%
—
—
cases:4.68%
controls:0.00%
—
—
cases:6.92%
controls:2.10%
cases:16.54%
controls:4.99%
21
63
149
1609
20
30
151
1652
—
8
0
163
1682
—
11
34
148
1585
21
68
106
1294
amitriptyline; oral, parenteral
N06AA09 [21604696]
1.3e+00
1.7e+00
2.3e+00
—
—
1.6e+00
6.4e-01
cases:13.53%
controls:4.25%
cases:8.19%
controls:1.61%
cases:2.92%
controls:0.30%
—
—
—
—
cases:8.81%
controls:1.91%
cases:7.87%
controls:4.33%
23
71
147
1601
14
27
157
1655
5
5
166
1677
—
—
14
31
145
1588
10
59
117
1303
Transferrin [Mass/volume] in Serum or Plasma
3034-6 [3004789]
9.6e-01
1.5e+00
—
—
—
1.6e+00
1.2e+00
cases:5.29%
controls:2.09%
cases:5.85%
controls:1.31%
—
—
—
—
—
—
cases:6.92%
controls:1.42%
cases:14.17%
controls:4.63%
9
35
161
1637
10
22
161
1660
—
—
—
11
23
148
1596
18
63
109
1299
Prolactin [Units/volume] in Serum or Plasma
15081-3 [3021387]
2.0e+00
—
1.0e+50
—
—
—
2.3e+00
cases:5.29%
controls:0.72%
—
—
cases:2.92%
controls:0.00%
—
—
—
—
—
—
cases:6.30%
controls:0.66%
9
12
161
1660
—
5
0
166
1682
—
—
—
8
9
119
1353
pH of Urine
2756-5 [3015736]
4.9e-01
7.8e-01
1.9e+00
1.0e+50
2.5e+00
8.1e-01
1.6e-01
cases:12.94%
controls:8.31%
cases:10.53%
controls:5.11%
cases:4.09%
controls:0.65%
cases:4.09%
controls:0.00%
cases:4.71%
controls:0.42%
cases:10.69%
controls:5.06%
cases:16.54%
controls:14.46%
22
139
148
1533
18
86
153
1596
7
11
164
1671
7
0
164
1682
8
7
162
1673
17
82
142
1537
21
197
106
1165
Upper gastrointestinal surgery
106 [44777669]
3.8e-01
9.2e-01
—
—
2.0e+00
1.3e+00
1.1e+00
cases:13.53%
controls:9.63%
cases:8.77%
controls:3.69%
—
—
—
—
cases:4.12%
controls:0.60%
cases:11.95%
controls:3.52%
cases:23.62%
controls:9.77%
23
161
147
1511
15
62
156
1620
—
—
7
10
163
1670
19
57
140
1562
30
133
97
1229
Trochanteric bursitis
M70.6 [45606304]
1.6e+00
2.7e+00
—
—
—
—
—
cases:5.29%
controls:1.08%
cases:4.09%
controls:0.30%
—
—
—
—
—
—
—
—
—
—
9
18
161
1654
7
5
164
1677
—
—
—
—
—
Lysozyme [Mass/volume] in Serum or Plasma
2589-0 [3012110]
2.2e+00
—
—
—
—
—
2.1e+00
cases:3.53%
controls:0.42%
—
—
—
—
—
—
—
—
—
—
cases:4.72%
controls:0.59%
6
7
164
1665
—
—
—
—
—
6
8
121
1354
Predominantly allergic asthma
J45.0 [45557624]
1.5e+00
—
—
—
—
—
2.5e+00
cases:5.29%
controls:1.20%
—
—
—
—
—
—
—
—
—
—
cases:11.02%
controls:1.03%
9
20
161
1652
—
—
—
—
—
14
14
113
1348
esomeprazole; oral, parenteral
A02BC05 [21600100]
8.9e-01
1.0e+00
9.7e-01
—
—
1.0e+00
1.1e+00
cases:17.65%
controls:8.07%
cases:11.11%
controls:4.40%
cases:2.92%
controls:1.13%
—
—
—
—
cases:10.06%
controls:3.95%
cases:18.90%
controls:7.49%
30
135
140
1537
19
74
152
1608
5
19
166
1663
—
—
16
64
143
1555
24
102
103
1260
pantoprazole; oral, parenteral
A02BC02 [21600097]
7.3e-01
1.1e+00
1.4e-01
—
1.2e+00
8.7e-01
5.6e-01
cases:32.35%
controls:18.66%
cases:23.98%
controls:9.69%
cases:2.92%
controls:2.56%
—
—
cases:8.82%
controls:2.74%
cases:21.38%
controls:10.25%
cases:32.28%
controls:21.44%
55
312
115
1360
41
163
130
1519
5
43
166
1639
—
15
46
155
1634
34
166
125
1453
41
292
86
1070
salbutamol; inhalant
R03AC02 [21603256]
8.2e-01
1.1e+00
—
—
1.2e+00
9.6e-01
1.0e+00
cases:28.24%
controls:14.71%
cases:18.71%
controls:7.25%
—
—
—
—
cases:4.71%
controls:1.43%
cases:17.61%
controls:7.60%
cases:33.07%
controls:15.20%
48
246
122
1426
32
122
139
1560
—
—
8
24
162
1656
28
123
131
1496
42
207
85
1155
Neurosurgery
14 [38004459]
9.6e-01
1.8e+00
—
—
—
2.1e+00
8.2e-01
cases:5.88%
controls:2.33%
cases:4.68%
controls:0.83%
—
—
—
—
—
—
cases:5.66%
controls:0.74%
cases:4.72%
controls:2.13%
10
39
160
1633
8
14
163
1668
—
—
—
9
12
150
1607
6
29
121
1333
Hypothyroidism, unspecified
E03.9 [45537945]
1.5e+00
2.2e+00
—
1.0e+50
—
1.7e+00
1.1e+00
cases:7.06%
controls:1.61%
cases:5.85%
controls:0.65%
—
—
cases:2.92%
controls:0.00%
—
—
cases:4.40%
controls:0.80%
cases:6.30%
controls:2.28%
12
27
158
1645
10
11
161
1671
—
5
0
166
1682
—
7
13
152
1606
8
31
119
1331
codeine and paracetamol
N02AJ06 [1123647]
7.1e-01
1.2e+00
1.8e+00
—
1.3e+00
8.7e-01
6.1e-01
cases:25.88%
controls:14.59%
cases:15.79%
controls:5.41%
cases:5.26%
controls:0.89%
—
—
cases:3.53%
controls:0.95%
cases:10.69%
controls:4.76%
cases:22.05%
controls:13.29%
44
244
126
1428
27
91
144
1591
9
15
162
1667
—
6
16
164
1664
17
77
142
1542
28
181
99
1181
Esophagoscopy, gastroscopy and duodenoscopy
UJD10 [2001304788]
7.7e-01
1.1e+00
—
—
—
2.0e+00
1.7e+00
cases:8.82%
controls:4.31%
cases:4.09%
controls:1.43%
—
—
—
—
—
—
cases:8.81%
controls:1.24%
cases:15.75%
controls:3.38%
15
72
155
1600
7
24
164
1658
—
—
—
14
20
145
1599
20
46
107
1316
Infectious Disease
44 [38004484]
1.3e+00
1.8e+00
—
—
—
1.5e+00
1.9e+00
cases:5.29%
controls:1.44%
cases:4.68%
controls:0.83%
—
—
—
—
—
—
cases:3.14%
controls:0.74%
cases:9.45%
controls:1.54%
9
24
161
1648
8
14
163
1668
—
—
—
5
12
154
1607
12
21
115
1341
Phosphate [Moles/volume] in Serum or Plasma
14879-1 [3003458]
1.1e+00
1.7e+00
—
—
2.1e+00
1.5e+00
1.9e+00
cases:5.29%
controls:1.79%
cases:7.02%
controls:1.31%
—
—
—
—
cases:2.94%
controls:0.36%
cases:5.03%
controls:1.11%
cases:16.54%
controls:2.94%
9
30
161
1642
12
22
159
1660
—
—
5
6
165
1674
8
18
151
1601
21
40
106
1322
Albumin [Presence] in Urine by Test strip
50949-7 [3029937]
7.1e-01
8.0e-01
1.6e+00
1.0e+50
2.3e+00
1.2e+00
4.8e-01
cases:10.59%
controls:5.50%
cases:8.19%
controls:3.86%
cases:3.51%
controls:0.71%
cases:5.26%
controls:0.00%
cases:4.12%
controls:0.42%
cases:11.32%
controls:3.83%
cases:15.75%
controls:10.35%
18
92
152
1580
14
65
157
1617
6
12
165
1670
9
0
162
1682
7
7
163
1673
18
62
141
1557
20
141
107
1221
Acute bronchitis, unspecified
J20.9 [45562445]
1.0e+00
2.0e+00
—
—
—
—
1.5e+00
cases:5.88%
controls:2.21%
cases:5.26%
controls:0.77%
—
—
—
—
—
—
—
—
cases:7.87%
controls:1.91%
10
37
160
1635
9
13
162
1669
—
—
—
—
10
26
117
1336
Stomach Pathology biopsy report
66114-0 [40768797]
1.0e+00
1.0e+00
—
—
—
1.9e+00
1.5e+00
cases:5.29%
controls:1.97%
cases:2.92%
controls:1.07%
—
—
—
—
—
—
cases:5.03%
controls:0.80%
cases:10.24%
controls:2.42%
9
33
161
1639
5
18
166
1664
—
—
—
8
13
151
1606
13
33
114
1329
duloxetine; oral
N06AX21 [21604749]
1.9e+00
1.6e+00
2.3e+00
—
—
1.3e+00
1.5e+00
cases:8.24%
controls:1.38%
cases:4.68%
controls:1.01%
cases:2.92%
controls:0.30%
—
—
—
—
cases:3.77%
controls:1.05%
cases:9.45%
controls:2.20%
14
23
156
1649
8
17
163
1665
5
5
166
1677
—
—
6
17
153
1602
12
30
115
1332
Dyspnoea
R06.0 [45558449]
8.4e-01
1.7e+00
—
—
—
1.3e+00
1.6e+00
cases:8.82%
controls:4.01%
cases:7.02%
controls:1.31%
—
—
—
—
—
—
cases:5.66%
controls:1.67%
cases:15.75%
controls:3.52%
15
67
155
1605
12
22
159
1660
—
—
—
9
27
150
1592
20
48
107
1314
cefalexin; oral
J01DB01 [21602870]
8.4e-01
8.6e-01
—
—
1.5e+00
9.0e-01
7.6e-01
cases:44.71%
controls:25.84%
cases:19.30%
controls:9.16%
—
—
—
—
cases:2.94%
controls:0.65%
cases:15.72%
controls:7.04%
cases:40.16%
controls:23.86%
76
432
94
1240
33
154
138
1528
—
—
5
11
165
1669
25
114
134
1505
51
325
76
1037
Methicillin resistant Staphylococcus aureus [Presence] in Specimen by Organism specific culture
13317-3 [3019902]
7.6e-01
1.8e+00
—
—
—
—
1.5e+00
cases:3.53%
controls:1.67%
cases:4.09%
controls:0.71%
—
—
—
—
—
—
—
—
cases:8.66%
controls:2.06%
6
28
164
1644
7
12
164
1670
—
—
—
—
11
28
116
1334
12 lead EKG panel
34534-8 [3044889]
3.5e-01
6.5e-01
1.1e+00
—
2.3e+00
1.0e+00
4.9e-01
cases:23.53%
controls:17.82%
cases:18.13%
controls:10.34%
cases:4.09%
controls:1.43%
—
—
cases:10.00%
controls:1.13%
cases:22.64%
controls:9.76%
cases:33.07%
controls:23.20%
40
298
130
1374
31
174
140
1508
7
24
164
1658
—
17
19
153
1661
36
158
123
1461
42
316
85
1046
Epithelial cells [#/volume] in Urine
30383-4 [3000850]
7.2e-01
1.8e+00
—
—
—
1.0e+00
1.4e+00
cases:7.65%
controls:3.89%
cases:9.36%
controls:1.61%
—
—
—
—
—
—
cases:6.29%
controls:2.35%
cases:18.90%
controls:5.36%
13
65
157
1607
16
27
155
1655
—
—
—
10
38
149
1581
24
73
103
1289
spironolactone; oral
C03DA01 [21601534]
1.3e+00
1.8e+00
—
—
—
1.5e+00
1.5e+00
cases:5.88%
controls:1.61%
cases:5.26%
controls:0.95%
—
—
—
—
—
—
cases:5.66%
controls:1.36%
cases:8.66%
controls:2.13%
10
27
160
1645
9
16
162
1666
—
—
—
9
22
150
1597
11
29
116
1333
General Surgery
2 [38004447]
6.7e-01
1.2e+00
1.7e+00
—
—
1.4e+00
2.8e-01
cases:25.29%
controls:14.77%
cases:13.45%
controls:4.52%
cases:2.92%
controls:0.54%
—
—
—
—
cases:12.58%
controls:3.58%
cases:16.54%
controls:13.07%
43
247
127
1425
23
76
148
1606
5
9
166
1673
—
—
20
58
139
1561
21
178
106
1184
Rheumatoid factor [Units/volume] in Serum or Plasma
11572-5 [3021614]
6.1e-01
2.0e+00
—
—
—
1.7e+00
1.2e+00
cases:7.65%
controls:4.31%
cases:6.43%
controls:0.89%
—
—
—
—
—
—
cases:3.77%
controls:0.74%
cases:13.39%
controls:4.55%
13
72
157
1600
11
15
160
1667
—
—
—
6
12
153
1607
17
62
110
1300
Urology
34 [38004474]
9.3e-01
1.0e+00
—
—
—
1.2e+00
8.2e-01
cases:13.53%
controls:5.80%
cases:9.94%
controls:3.80%
—
—
—
—
—
—
cases:10.69%
controls:3.34%
cases:13.39%
controls:6.39%
23
97
147
1575
17
64
154
1618
—
—
—
17
54
142
1565
17
87
110
1275
Extensive structural and functional ultrasound examination of heart
FM1EE [2001303307]
3.6e-01
1.0e+00
—
—
1.0e+50
1.7e+00
1.4e+00
cases:5.29%
controls:3.77%
cases:3.51%
controls:1.31%
—
—
—
—
cases:2.94%
controls:0.00%
cases:5.66%
controls:1.11%
cases:13.39%
controls:3.52%
9
63
161
1609
6
22
165
1660
—
—
5
0
165
1680
9
18
150
1601
17
48
110
1314
Fasting glucose [Moles/volume] in Serum or Plasma
14771-0 [3018251]
2.7e-01
6.1e-01
1.5e+00
—
1.5e+00
6.3e-01
2.0e-01
cases:37.06%
controls:31.10%
cases:27.49%
controls:17.06%
cases:8.19%
controls:1.90%
—
—
cases:7.06%
controls:1.61%
cases:27.04%
controls:16.43%
cases:46.46%
controls:41.56%
63
520
107
1152
47
287
124
1395
14
32
157
1650
—
12
27
158
1653
43
266
116
1353
59
566
68
796
Office Visit
OMOP4822458 [581477]
5.9e-01
1.1e+00
—
—
—
1.6e+00
1.4e+00
cases:15.29%
controls:9.09%
cases:7.02%
controls:2.44%
—
—
—
—
—
—
cases:9.43%
controls:2.04%
cases:21.26%
controls:6.02%
26
152
144
1520
12
41
159
1641
—
—
—
15
33
144
1586
27
82
100
1280
Cobalamin (Vitamin B12) [Moles/volume] in Serum or Plasma
14685-2 [3009035]
6.6e-01
1.4e+00
—
—
—
1.6e+00
8.4e-01
cases:9.41%
controls:5.08%
cases:6.43%
controls:1.66%
—
—
—
—
—
—
cases:7.55%
controls:1.61%
cases:13.39%
controls:6.24%
16
85
154
1587
11
28
160
1654
—
—
—
12
26
147
1593
17
85
110
1277
hydrocortisone
S01CB03 [21603666]
—
—
—
—
—
—
3.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.87%
controls:0.44%
—
—
—
—
—
—
10
6
117
1356
hydrocortisone
S01BA02 [21603619]
—
—
—
—
—
—
3.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.87%
controls:0.44%
—
—
—
—
—
—
10
6
117
1356
Protein [Presence] in Urine by Test strip
20454-5 [3014051]
5.4e-01
7.0e-01
—
—
2.9e+00
5.7e-01
1.9e-01
cases:7.06%
controls:4.25%
cases:5.26%
controls:2.68%
—
—
—
—
cases:5.29%
controls:0.30%
cases:5.66%
controls:3.27%
cases:10.24%
controls:8.59%
12
71
158
1601
9
45
162
1637
—
—
9
5
161
1675
9
53
150
1566
13
117
114
1245
Observation for other suspected diseases and conditions
Z03.80 [2000503756]
2.9e+00
—
—
—
1.0e+50
—
—
cases:5.29%
controls:0.30%
—
—
—
—
—
—
cases:4.12%
controls:0.00%
—
—
—
—
9
5
161
1667
—
—
—
7
0
163
1680
—
—
Extensive MRI examination of brain with high intensity magnet
AA1CG [2001300116]
—
—
—
—
—
—
2.9e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.30%
controls:0.37%
—
—
—
—
—
—
8
5
119
1357
tizanidine; oral
M03BX02 [21604116]
7.0e-01
1.2e+00
—
—
—
1.0e+00
5.2e-01
cases:21.76%
controls:12.14%
cases:11.11%
controls:3.80%
—
—
—
—
—
—
cases:10.69%
controls:4.14%
cases:16.54%
controls:10.50%
37
203
133
1469
19
64
152
1618
—
—
—
17
67
142
1552
21
143
106
1219
Iron/Transferrin [Ratio] in Serum or Plasma
60517-0 [40763571]
8.2e-01
1.5e+00
—
—
—
1.5e+00
1.3e+00
cases:4.12%
controls:1.85%
cases:4.68%
controls:1.13%
—
—
—
—
—
—
cases:5.66%
controls:1.30%
cases:13.39%
controls:4.11%
7
31
163
1641
8
19
163
1663
—
—
—
9
21
150
1598
17
56
110
1306
Pneumonia, unspecified
J18.9 [45601123]
8.5e-01
1.3e+00
—
—
—
1.4e+00
1.4e+00
cases:7.65%
controls:3.41%
cases:3.51%
controls:1.01%
—
—
—
—
—
—
cases:6.29%
controls:1.61%
cases:13.39%
controls:3.74%
13
57
157
1615
6
17
165
1665
—
—
—
10
26
149
1593
17
51
110
1311
Iron [Moles/volume] in Serum or Plasma
14798-3 [3022948]
8.8e-01
1.3e+00
—
—
—
1.5e+00
1.3e+00
cases:5.29%
controls:2.27%
cases:5.26%
controls:1.49%
—
—
—
—
—
—
cases:6.92%
controls:1.61%
cases:14.96%
controls:4.77%
9
38
161
1634
9
25
162
1657
—
—
—
11
26
148
1593
19
65
108
1297
Blood type and Crossmatch panel - Blood
34531-4 [3044640]
-1.2e-01
1.2e+00
—
—
—
1.5e+00
7.3e-01
cases:5.88%
controls:6.58%
cases:9.94%
controls:3.09%
—
—
—
—
—
—
cases:9.43%
controls:2.22%
cases:14.17%
controls:7.34%
10
110
160
1562
17
52
154
1630
—
—
—
15
36
144
1583
18
100
109
1262
paracetamol; oral, parenteral, rectal
N02BE01 [21604344]
5.6e-01
6.0e-01
1.1e+00
—
1.1e+00
4.3e-01
3.8e-01
cases:48.24%
controls:34.75%
cases:29.82%
controls:18.97%
cases:8.19%
controls:2.85%
—
—
cases:9.41%
controls:3.45%
cases:26.42%
controls:18.96%
cases:50.39%
controls:41.04%
82
581
88
1091
51
319
120
1363
14
48
157
1634
—
16
58
154
1622
42
307
117
1312
64
559
63
803
Specific gravity of Urine by Refractometry
5810-7 [3019150]
3.8e-01
6.5e-01
—
—
2.7e+00
3.1e-01
3.2e-02
cases:7.65%
controls:5.38%
cases:5.85%
controls:3.15%
—
—
—
—
cases:4.12%
controls:0.30%
cases:4.40%
controls:3.27%
cases:9.45%
controls:9.18%
13
90
157
1582
10
53
161
1629
—
—
7
5
163
1675
7
53
152
1566
12
125
115
1237
Sleep apnoea
G47.3 [45562094]
5.7e-01
6.9e-01
—
—
—
1.4e+00
1.2e+00
cases:7.65%
controls:4.49%
cases:5.85%
controls:3.03%
—
—
—
—
—
—
cases:11.95%
controls:3.15%
cases:15.75%
controls:5.29%
13
75
157
1597
10
51
161
1631
—
—
—
19
51
140
1568
20
72
107
1290
Pain in limb
M79.6 [45587063]
9.7e-01
8.2e-01
—
—
—
1.6e+00
7.8e-01
cases:14.71%
controls:6.16%
cases:7.02%
controls:3.21%
—
—
—
—
—
—
cases:12.58%
controls:2.72%
cases:18.90%
controls:9.69%
25
103
145
1569
12
54
159
1628
—
—
—
20
44
139
1575
24
132
103
1230
Band form neutrophils/Leukocytes in Blood
26508-2 [3004809]
—
—
—
—
—
—
2.6e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.72%
controls:0.37%
—
—
—
—
—
—
6
5
121
1357
Ambulatory ECG
XF404 [2001303370]
—
—
—
—
—
—
2.6e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.51%
controls:0.44%
—
—
—
—
—
—
7
6
120
1356
Angiotensin converting enzyme [Enzymatic activity/volume] in Serum or Plasma
2742-5 [3034780]
1.8e+00
—
—
—
—
—
2.5e+00
cases:3.53%
controls:0.60%
—
—
—
—
—
—
—
—
—
—
cases:7.87%
controls:0.66%
6
10
164
1662
—
—
—
—
—
10
9
117
1353
warfarin; oral, parenteral
B01AA03 [21600965]
1.2e+00
1.3e+00
1.8e+00
—
—
8.3e-01
6.9e-01
cases:11.18%
controls:3.65%
cases:9.94%
controls:2.79%
cases:2.92%
controls:0.48%
—
—
—
—
cases:6.29%
controls:2.84%
cases:7.09%
controls:3.67%
19
61
151
1611
17
47
154
1635
5
8
166
1674
—
—
10
46
149
1573
9
50
118
1312
Fibrin D-dimer FEU [Mass/volume] in Platelet poor plasma
48065-7 [3051714]
1.0e+00
7.9e-01
2.1e+00
—
—
1.2e+00
1.5e+00
cases:10.59%
controls:4.07%
cases:4.09%
controls:1.90%
cases:2.92%
controls:0.36%
—
—
—
—
cases:4.40%
controls:1.36%
cases:18.11%
controls:4.63%
18
68
152
1604
7
32
164
1650
5
6
166
1676
—
—
7
22
152
1597
23
63
104
1299
Extensive abdominal CT
JN3BD [2001305556]
—
—
—
—
—
2.5e+00
—
—
—
—
—
—
—
—
—
—
—
cases:3.77%
controls:0.31%
—
—
—
—
—
—
—
6
5
153
1614
—
Prealbumin [Mass/volume] in Serum or Plasma
14338-8 [3013742]
—
—
—
—
—
2.5e+00
1.4e+00
—
—
—
—
—
—
—
—
—
—
cases:3.77%
controls:0.31%
cases:5.51%
controls:1.47%
—
—
—
—
—
6
5
153
1614
7
20
120
1342
Bacteria identified in Blood by Culture
600-7 [3023368]
6.8e-01
1.3e+00
—
—
—
1.2e+00
1.2e+00
cases:8.82%
controls:4.67%
cases:7.60%
controls:2.14%
—
—
—
—
—
—
cases:7.55%
controls:2.35%
cases:18.90%
controls:6.53%
15
78
155
1594
13
36
158
1646
—
—
—
12
38
147
1581
24
89
103
1273
Rheumatology
66 [38004491]
1.0e+00
1.2e+00
—
—
—
1.3e+00
1.5e+00
cases:8.82%
controls:3.35%
cases:6.43%
controls:1.96%
—
—
—
—
—
—
cases:5.03%
controls:1.42%
cases:13.39%
controls:3.38%
15
56
155
1616
11
33
160
1649
—
—
—
8
23
151
1596
17
46
110
1316
Transferrin.carbohydrate deficient.disialo/Transferrin.total in Serum or Plasma
21573-1 [3003031]
—
—
—
—
—
2.5e+00
7.5e-01
—
—
—
—
—
—
—
—
—
—
cases:5.03%
controls:0.43%
cases:6.30%
controls:3.08%
—
—
—
—
—
8
7
151
1612
8
42
119
1320
Constipation, unspecified
K59.09 [2000502926]
2.5e+00
—
—
—
—
—
1.9e+00
cases:3.53%
controls:0.30%
—
—
—
—
—
—
—
—
—
—
cases:4.72%
controls:0.73%
6
5
164
1667
—
—
—
—
—
6
10
121
1352
Abdominal X-ray examination without contrast
JN3AA [2001305553]
2.5e+00
—
—
—
—
—
—
cases:3.53%
controls:0.30%
—
—
—
—
—
—
—
—
—
—
—
—
6
5
164
1667
—
—
—
—
—
—
Calcium [Moles/volume] in Serum or Plasma
2000-8 [3015377]
4.6e-01
9.2e-01
—
—
—
1.3e+00
1.2e+00
cases:8.82%
controls:5.74%
cases:7.02%
controls:2.91%
—
—
—
—
—
—
cases:9.43%
controls:2.72%
cases:22.05%
controls:8.08%
15
96
155
1576
12
49
159
1633
—
—
—
15
44
144
1575
28
110
99
1252
Holo-transcobalamin II [Moles/volume] in Serum
72160-5 [43054903]
7.2e-01
7.9e-01
—
—
2.5e+00
9.2e-01
7.0e-01
cases:14.12%
controls:7.42%
cases:8.77%
controls:4.16%
—
—
—
—
cases:4.12%
controls:0.36%
cases:8.81%
controls:3.71%
cases:24.41%
controls:13.88%
24
124
146
1548
15
70
156
1612
—
—
7
6
163
1674
14
60
145
1559
31
189
96
1173
Oedema, unspecified
R60.9 [45568143]
2.5e+00
—
—
—
—
—
-1.0e+50
cases:4.12%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.51%
7
6
163
1666
—
—
—
—
—
0
7
127
1355
Hyaline casts [#/volume] in Urine by Automated count
51484-4 [3030981]
1.1e+00
2.5e+00
—
—
—
—
1.3e+00
cases:3.53%
controls:1.26%
cases:5.26%
controls:0.48%
—
—
—
—
—
—
—
—
cases:8.66%
controls:2.57%
6
21
164
1651
9
8
162
1674
—
—
—
—
11
35
116
1327
fluconazole; oral, parenteral
J02AC01 [21603080]
6.1e-01
8.9e-01
—
—
—
1.3e+00
1.1e+00
cases:13.53%
controls:7.83%
cases:5.85%
controls:2.50%
—
—
—
—
—
—
cases:8.18%
controls:2.29%
cases:14.96%
controls:5.51%
23
131
147
1541
10
42
161
1640
—
—
—
13
37
146
1582
19
75
108
1287
propranolol; oral, parenteral
C07AA05 [21601670]
4.4e-01
8.7e-01
—
—
—
1.4e+00
1.1e+00
cases:4.12%
controls:2.69%
cases:4.68%
controls:2.02%
—
—
—
—
—
—
cases:7.55%
controls:2.04%
cases:11.81%
controls:4.41%
7
45
163
1627
8
34
163
1648
—
—
—
12
33
147
1586
15
60
112
1302
Joint ultrasound examination not elsewhere classified
NK4XE [2001308469]
—
—
—
—
—
—
2.4e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.51%
controls:0.51%
—
—
—
—
—
—
7
7
120
1355
Procedure duration 50 to 59 minutes
ZXE06 [2001311400]
—
-1.0e+50
—
—
—
—
2.4e+00
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
cases:4.72%
controls:0.44%
—
0
6
171
1676
—
—
—
—
6
6
121
1356
Arthrocentesis, unspecified region, unspecified region
TNX10 [2001308560]
—
—
—
—
—
—
2.4e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.72%
controls:0.44%
—
—
—
—
—
—
6
6
121
1356
formoterol, glycopyrronium bromide and beclometasone
R03AL09 [1502099]
—
—
—
—
—
—
2.4e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.94%
controls:0.37%
—
—
—
—
—
—
5
5
122
1357
Bacteria identified in Sputum by Culture
6460-0 [3023419]
—
—
—
—
—
—
2.4e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.94%
controls:0.37%
—
—
—
—
—
—
5
5
122
1357
Social worker
Z2446 [2001311559]
—
-1.0e+50
—
—
—
—
2.4e+00
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
cases:3.94%
controls:0.37%
—
0
6
171
1676
—
—
—
—
5
5
122
1357
norfloxacin; oral
J01MA06 [21603013]
1.4e+00
—
—
—
—
—
2.4e+00
cases:2.94%
controls:0.78%
—
—
—
—
—
—
—
—
—
—
cases:3.94%
controls:0.37%
5
13
165
1659
—
—
—
—
—
5
5
122
1357
Asthma
J45 [45596282]
8.5e-01
—
—
—
—
2.4e+00
9.9e-01
cases:4.12%
controls:1.79%
—
—
—
—
—
—
—
—
cases:3.77%
controls:0.37%
cases:5.51%
controls:2.13%
7
30
163
1642
—
—
—
—
6
6
153
1613
7
29
120
1333
loperamide oxide; oral
A07DA05 [21600648]
—
—
—
—
—
2.4e+00
—
—
—
—
—
—
—
—
—
—
—
cases:3.77%
controls:0.37%
—
—
—
—
—
—
—
6
6
153
1613
—
loperamide; oral
A07DA03 [21600646]
—
—
—
—
—
2.4e+00
—
—
—
—
—
—
—
—
—
—
—
cases:3.77%
controls:0.37%
—
—
—
—
—
—
—
6
6
153
1613
—
Anesthesiology Critical Care Medicine
OMOP4821991 [45756751]
—
—
—
—
—
1.9e+00
2.3e+00
—
—
—
—
—
—
—
—
—
—
cases:3.14%
controls:0.49%
cases:7.87%
controls:0.81%
—
—
—
—
—
5
8
154
1611
10
11
117
1351
Lutropin [Units/volume] in Serum or Plasma
10501-5 [3009214]
2.3e+00
—
—
—
—
—
2.1e+00
cases:3.53%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
cases:3.94%
controls:0.51%
6
6
164
1666
—
—
—
—
—
5
7
122
1355
Catheterisation of bladder
TKC20 [2001306020]
2.3e+00
—
—
—
—
—
—
cases:3.53%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
—
—
6
6
164
1666
—
—
—
—
—
—
formoterol and beclometasone
R03AK08 [43534839]
—
—
—
—
—
2.2e+00
2.3e+00
—
—
—
—
—
—
—
—
—
—
cases:3.14%
controls:0.37%
cases:6.30%
controls:0.66%
—
—
—
—
—
5
6
154
1613
8
9
119
1353
Testosterone [Moles/volume] in Serum or Plasma
14913-8 [3017446]
1.1e+00
1.7e+00
—
—
—
2.3e+00
1.1e+00
cases:4.71%
controls:1.61%
cases:4.09%
controls:0.77%
—
—
—
—
—
—
cases:6.92%
controls:0.74%
cases:5.51%
controls:1.98%
8
27
162
1645
7
13
164
1669
—
—
—
11
12
148
1607
7
27
120
1335
bisoprolol; oral
C07AB07 [21601689]
7.2e-01
7.8e-01
5.7e-01
—
5.7e-01
7.8e-01
5.7e-01
cases:24.12%
controls:13.40%
cases:23.98%
controls:12.60%
cases:7.02%
controls:4.10%
—
—
cases:7.06%
controls:4.11%
cases:25.16%
controls:13.34%
cases:25.20%
controls:16.01%
41
224
129
1448
41
212
130
1470
12
69
159
1613
—
12
69
158
1611
40
216
119
1403
32
218
95
1144
Parathyrin.intact [Moles/volume] in Serum or Plasma
14866-8 [3010566]
—
—
—
—
—
—
2.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.72%
controls:0.51%
—
—
—
—
—
—
6
7
121
1355
Blood group antibody screen [Presence] in Serum or Plasma
890-4 [3001079]
2.8e-01
1.1e+00
—
—
—
1.1e+00
6.2e-01
cases:12.94%
controls:10.11%
cases:14.04%
controls:4.99%
—
—
—
—
—
—
cases:10.06%
controls:3.58%
cases:18.90%
controls:11.16%
22
169
148
1503
24
84
147
1598
—
—
—
16
58
143
1561
24
152
103
1210
Influenza virus B RNA [Presence] in Nasopharynx by NAA with probe detection
76080-1 [46235759]
—
—
—
—
—
—
2.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.09%
controls:0.81%
—
—
—
—
—
—
9
11
118
1351
Clinical & Laboratory Dermatological Immunology Physician
207NI0002X [38003841]
1.1e+00
1.1e+00
1.8e+00
—
1.8e+00
5.5e-01
5.4e-01
cases:16.47%
controls:6.22%
cases:8.19%
controls:2.79%
cases:2.92%
controls:0.48%
—
—
cases:3.53%
controls:0.60%
cases:4.40%
controls:2.59%
cases:11.02%
controls:6.75%
28
104
142
1568
14
47
157
1635
5
8
166
1674
—
6
10
164
1670
7
42
152
1577
14
92
113
1270
Nonallergic asthma
J45.1 [45557625]
1.8e+00
—
—
—
—
—
2.2e+00
cases:3.53%
controls:0.60%
—
—
—
—
—
—
—
—
—
—
cases:6.30%
controls:0.73%
6
10
164
1662
—
—
—
—
—
8
10
119
1352
moxifloxacin; oral, parenteral
J01MA14 [21603021]
2.2e+00
—
—
—
—
—
—
cases:4.12%
controls:0.48%
—
—
—
—
—
—
—
—
—
—
—
—
7
8
163
1664
—
—
—
—
—
—
Pain general/multiple sites
A01 [2002000142]
1.5e+00
2.3e+00
—
—
—
—
2.2e+00
cases:2.94%
controls:0.66%
cases:2.92%
controls:0.30%
—
—
—
—
—
—
—
—
cases:7.87%
controls:0.95%
5
11
165
1661
5
5
166
1677
—
—
—
—
10
13
117
1349
gabapentin; oral
N02BF01 [955005]
1.1e+00
1.2e+00
1.8e+00
—
—
1.1e+00
1.1e+00
cases:8.24%
controls:2.99%
cases:5.85%
controls:1.78%
cases:2.92%
controls:0.48%
—
—
—
—
cases:5.03%
controls:1.79%
cases:11.02%
controls:3.96%
14
50
156
1622
10
30
161
1652
5
8
166
1674
—
—
8
29
151
1590
14
54
113
1308
Colonoscopy Study observation
28023-0 [3022145]
9.6e-01
2.2e+00
—
—
—
—
1.2e+00
cases:4.12%
controls:1.61%
cases:3.51%
controls:0.42%
—
—
—
—
—
—
—
—
cases:8.66%
controls:2.79%
7
27
163
1645
6
7
165
1675
—
—
—
—
11
38
116
1324
Urgent procedure
ZXD05 [2001311386]
6.8e-01
1.0e+00
—
—
—
2.1e+00
1.1e+00
cases:8.24%
controls:4.37%
cases:2.92%
controls:1.07%
—
—
—
—
—
—
cases:5.03%
controls:0.62%
cases:8.66%
controls:3.16%
14
73
156
1599
5
18
166
1664
—
—
—
8
10
151
1609
11
43
116
1319
SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory system specimen by NAA with probe detection
94500-6 [706163]
2.2e-01
5.0e-01
1.5e+00
—
2.1e+00
2.3e-01
6.8e-01
cases:12.35%
controls:10.17%
cases:8.77%
controls:5.53%
cases:3.51%
controls:0.83%
—
—
cases:5.29%
controls:0.65%
cases:8.18%
controls:6.61%
cases:29.92%
controls:17.84%
21
170
149
1502
15
93
156
1589
6
14
165
1668
—
9
11
161
1669
13
107
146
1512
38
243
89
1119
HLA-B27 [Presence]
4821-5 [3008898]
1.4e+00
—
—
—
—
—
2.1e+00
cases:2.94%
controls:0.72%
—
—
—
—
—
—
—
—
—
—
cases:4.72%
controls:0.59%
5
12
165
1660
—
—
—
—
—
6
8
121
1354
Extensive CT examination of arteria pulmonalis
FB1BD [2001302407]
—
—
—
—
—
—
2.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.72%
controls:0.59%
—
—
—
—
—
—
6
8
121
1354
Respiratory syncytial virus RNA [Presence] in Specimen by NAA with probe detection
40988-8 [3044254]
—
—
—
—
—
—
2.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.72%
controls:0.59%
—
—
—
—
—
—
6
8
121
1354
Bicarbonate [Moles/volume] standard in Capillary blood
19231-0 [3004490]
—
—
—
—
—
—
2.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.72%
controls:0.59%
—
—
—
—
—
—
6
8
121
1354
Hepatitis C virus Ab [Presence] in Serum
16128-1 [3017143]
6.8e-01
—
—
—
—
2.1e+00
1.3e+00
cases:5.29%
controls:2.75%
—
—
—
—
—
—
—
—
cases:4.40%
controls:0.56%
cases:6.30%
controls:1.76%
9
46
161
1626
—
—
—
—
7
9
152
1610
8
24
119
1338
Migraine, unspecified
G43.9 [45595943]
2.1e+00
—
—
—
—
—
—
cases:4.71%
controls:0.60%
—
—
—
—
—
—
—
—
—
—
—
—
8
10
162
1662
—
—
—
—
—
—
cetirizine; oral
R06AE07 [21603497]
3.4e-01
9.9e-01
—
—
2.1e+00
7.9e-01
7.8e-01
cases:11.76%
controls:8.67%
cases:8.77%
controls:3.45%
—
—
—
—
cases:4.12%
controls:0.54%
cases:7.55%
controls:3.58%
cases:16.54%
controls:8.30%
20
145
150
1527
15
58
156
1624
—
—
7
9
163
1671
12
58
147
1561
21
113
106
1249
ondansetron; oral, parenteral, rectal
A04AA01 [21600493]
—
—
—
—
—
—
2.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.51%
controls:0.73%
—
—
—
—
—
—
7
10
120
1352
Thyroperoxidase Ab [Units/volume] in Serum or Plasma
8099-4 [3027238]
9.2e-01
2.0e+00
—
—
—
—
7.4e-01
cases:2.94%
controls:1.20%
cases:5.26%
controls:0.71%
—
—
—
—
—
—
—
—
cases:3.94%
controls:1.91%
5
20
165
1652
9
12
162
1670
—
—
—
—
5
26
122
1336
Oxygen [Partial pressure] in Venous blood
2705-2 [3024354]
2.0e+00
1.3e+00
—
—
—
—
8.0e-01
cases:6.47%
controls:0.90%
cases:3.51%
controls:1.01%
—
—
—
—
—
—
—
—
cases:6.30%
controls:2.94%
11
15
159
1657
6
17
165
1665
—
—
—
—
8
40
119
1322
Check up of cardiac pacemaker
XFP20 [2001303367]
1.3e+00
2.0e+00
—
—
—
—
—
cases:3.53%
controls:1.02%
cases:3.51%
controls:0.48%
—
—
—
—
—
—
—
—
—
—
6
17
164
1655
6
8
165
1674
—
—
—
—
—
Nausea and vomiting
R11 [45539317]
—
—
—
—
—
—
2.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.30%
controls:0.88%
—
—
—
—
—
—
8
12
119
1350
potassium chloride; oral
A12BA01 [21600877]
1.1e+00
2.0e+00
—
—
—
1.6e+00
1.2e+00
cases:5.29%
controls:1.79%
cases:4.68%
controls:0.65%
—
—
—
—
—
—
cases:4.40%
controls:0.93%
cases:7.09%
controls:2.20%
9
30
161
1642
8
11
163
1671
—
—
—
7
15
152
1604
9
30
118
1332
Extractable nuclear Ab [Units/volume] in Serum
30342-0 [3015171]
1.7e+00
—
—
—
—
—
2.0e+00
cases:2.94%
controls:0.54%
—
—
—
—
—
—
—
—
—
—
cases:4.72%
controls:0.66%
5
9
165
1663
—
—
—
—
—
6
9
121
1353
Panorama tomography of teeth and jaws or similar X-ray examination
EB1HA [2001301913]
9.8e-01
4.4e-01
—
—
—
8.6e-01
1.0e+00
cases:18.82%
controls:8.01%
cases:2.92%
controls:1.90%
—
—
—
—
—
—
cases:5.66%
controls:2.47%
cases:18.11%
controls:7.34%
32
134
138
1538
5
32
166
1650
—
—
—
9
40
150
1579
23
100
104
1262
Bilirubin.conjugated [Moles/volume] in Serum or Plasma
29760-6 [3005772]
1.0e+00
1.7e+00
—
—
—
2.0e+00
1.1e+00
cases:4.71%
controls:1.73%
cases:2.92%
controls:0.54%
—
—
—
—
—
—
cases:5.03%
controls:0.74%
cases:10.24%
controls:3.82%
8
29
162
1643
5
9
166
1673
—
—
—
8
12
151
1607
13
52
114
1310
Coloscopy
UJF32 [2001305029]
8.8e-01
—
—
—
—
2.0e+00
9.7e-01
cases:9.41%
controls:4.13%
—
—
—
—
—
—
—
—
cases:5.03%
controls:0.74%
cases:8.66%
controls:3.45%
16
69
154
1603
—
—
—
—
8
12
151
1607
11
47
116
1315
Parathyrin.intact [Mass/volume] in Serum or Plasma
2731-8 [3000067]
—
—
—
—
—
—
1.9e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:9.45%
controls:1.47%
—
—
—
—
—
—
12
20
115
1342
macrogol; oral
A06AD15 [21600575]
1.1e+00
—
—
—
—
1.9e+00
8.2e-01
cases:3.53%
controls:1.20%
—
—
—
—
—
—
—
—
cases:4.40%
controls:0.68%
cases:4.72%
controls:2.13%
6
20
164
1652
—
—
—
—
7
11
152
1608
6
29
121
1333
hydroxyzine; oral, parenteral
N05BB01 [21604590]
7.0e-01
—
—
—
—
—
1.9e+00
cases:4.12%
controls:2.09%
—
—
—
—
—
—
—
—
—
—
cases:12.60%
controls:2.13%
7
35
163
1637
—
—
—
—
—
16
29
111
1333
diazepam; oral, parenteral, rectal
N05BA01 [21604566]
9.6e-01
1.9e+00
—
—
—
1.5e+00
9.1e-01
cases:5.88%
controls:2.33%
cases:7.02%
controls:1.13%
—
—
—
—
—
—
cases:5.03%
controls:1.11%
cases:6.30%
controls:2.64%
10
39
160
1633
12
19
159
1663
—
—
—
8
18
151
1601
8
36
119
1326
Extraction of root of tooth
EBA30 [2001301929]
—
—
—
—
—
—
1.9e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.51%
controls:0.88%
—
—
—
—
—
—
7
12
120
1350
Gas panel - Capillary blood
24337-8 [3022313]
—
—
—
—
—
—
1.9e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.51%
controls:0.88%
—
—
—
—
—
—
7
12
120
1350
aPTT in Platelet poor plasma by Coagulation assay
14979-9 [3018677]
9.4e-01
1.2e+00
—
—
—
1.9e+00
9.4e-01
cases:7.06%
controls:2.87%
cases:4.68%
controls:1.43%
—
—
—
—
—
—
cases:5.03%
controls:0.80%
cases:7.87%
controls:3.23%
12
48
158
1624
8
24
163
1658
—
—
—
8
13
151
1606
10
44
117
1318
Sampling
SPAT1263 [2001700364]
8.3e-01
1.0e+00
—
—
—
7.1e-01
6.8e-01
cases:20.00%
controls:9.87%
cases:8.77%
controls:3.27%
—
—
—
—
—
—
cases:6.92%
controls:3.52%
cases:18.11%
controls:10.06%
34
165
136
1507
15
55
156
1627
—
—
—
11
57
148
1562
23
137
104
1225
Lumbar and other intervertebral disc disorders with radiculopathy
M51.1 [45562747]
1.3e+00
1.9e+00
—
—
—
—
—
cases:5.29%
controls:1.50%
cases:4.09%
controls:0.65%
—
—
—
—
—
—
—
—
—
—
9
25
161
1647
7
11
164
1671
—
—
—
—
—
Headache
R51.80 [2000503603]
1.3e+00
1.9e+00
—
—
—
1.3e+00
—
cases:5.88%
controls:1.73%
cases:4.09%
controls:0.65%
—
—
—
—
—
—
cases:3.14%
controls:0.86%
—
—
10
29
160
1643
7
11
164
1671
—
—
—
5
14
154
1605
—
Bacterial infection, unspecified
A49.9 [45590816]
1.1e+00
—
—
—
—
—
1.9e+00
cases:4.12%
controls:1.44%
—
—
—
—
—
—
—
—
—
—
cases:6.30%
controls:1.03%
7
24
163
1648
—
—
—
—
—
8
14
119
1348
Follitropin [Units/volume] in Serum or Plasma
15067-2 [3023323]
1.3e+00
1.7e+00
—
—
—
—
1.9e+00
cases:3.53%
controls:1.02%
cases:2.92%
controls:0.54%
—
—
—
—
—
—
—
—
cases:6.30%
controls:1.03%
6
17
164
1655
5
9
166
1673
—
—
—
—
8
14
119
1348
amoxicillin; oral, parenteral
J01CA04 [21602823]
8.1e-01
1.0e+00
—
—
1.6e+00
5.2e-01
5.2e-01
cases:36.47%
controls:20.28%
cases:14.04%
controls:5.41%
—
—
—
—
cases:3.53%
controls:0.71%
cases:10.69%
controls:6.67%
cases:27.56%
controls:18.43%
62
339
108
1333
24
91
147
1591
—
—
6
12
164
1668
17
108
142
1511
35
251
92
1111
Base excess.100% oxygenated [Moles/volume] standard in Capillary blood by calculation
72720-6 [43055554]
—
—
—
—
—
1.6e+00
1.9e+00
—
—
—
—
—
—
—
—
—
—
cases:3.14%
controls:0.68%
cases:7.09%
controls:1.17%
—
—
—
—
—
5
11
154
1608
9
16
118
1346
pH of Capillary blood
2745-8 [3009343]
—
—
—
—
—
1.6e+00
1.9e+00
—
—
—
—
—
—
—
—
—
—
cases:3.14%
controls:0.68%
cases:7.09%
controls:1.17%
—
—
—
—
—
5
11
154
1608
9
16
118
1346
Carbon dioxide [Partial pressure] in Capillary blood
2020-6 [3023024]
—
—
—
—
—
1.5e+00
1.9e+00
—
—
—
—
—
—
—
—
—
—
cases:3.14%
controls:0.74%
cases:7.09%
controls:1.17%
—
—
—
—
—
5
12
154
1607
9
16
118
1346
Carbon dioxide [Partial pressure] in Venous blood
2021-4 [3021447]
1.8e+00
1.4e+00
—
—
—
—
8.0e-01
cases:7.06%
controls:1.20%
cases:4.68%
controls:1.19%
—
—
—
—
—
—
—
—
cases:7.09%
controls:3.30%
12
20
158
1652
8
20
163
1662
—
—
—
—
9
45
118
1317
IgE [Units/volume] in Serum or Plasma
19113-0 [3005322]
1.5e+00
—
—
—
—
—
1.8e+00
cases:4.12%
controls:0.96%
—
—
—
—
—
—
—
—
—
—
cases:7.87%
controls:1.40%
7
16
163
1656
—
—
—
—
—
10
19
117
1343
Obesity due to excess calories
E66.01 [2000501501]
1.5e+00
—
—
—
—
—
1.8e+00
cases:3.53%
controls:0.84%
—
—
—
—
—
—
—
—
—
—
cases:7.09%
controls:1.25%
6
14
164
1658
—
—
—
—
—
9
17
118
1345
Bicarbonate [Moles/volume] standard in Venous blood
19232-8 [3007628]
1.8e+00
—
—
—
—
—
—
cases:4.12%
controls:0.72%
—
—
—
—
—
—
—
—
—
—
—
—
7
12
163
1660
—
—
—
—
—
—
Supine thorax X-ray examination
GD1QA [2001303648]
9.2e-01
1.8e+00
—
—
—
1.4e+00
1.0e+00
cases:4.12%
controls:1.67%
cases:4.09%
controls:0.71%
—
—
—
—
—
—
cases:3.77%
controls:0.93%
cases:7.09%
controls:2.72%
7
28
163
1644
7
12
164
1670
—
—
—
6
15
153
1604
9
37
118
1325
Heart failure, unspecified
I50.9 [45576879]
1.8e+00
1.4e+00
—
—
—
1.5e+00
1.2e+00
cases:5.29%
controls:0.96%
cases:2.92%
controls:0.77%
—
—
—
—
—
—
cases:3.77%
controls:0.86%
cases:7.09%
controls:2.20%
9
16
161
1656
5
13
166
1669
—
—
—
6
14
153
1605
9
30
118
1332
Acute tubulo-interstitial nephritis
N10 [45543856]
—
—
—
—
—
—
1.7e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.87%
controls:1.47%
—
—
—
—
—
—
10
20
117
1342
Abdominal ultrasound examination
JN3AE [2001305555]
1.2e+00
1.3e+00
—
—
—
—
1.7e+00
cases:5.88%
controls:1.91%
cases:2.92%
controls:0.83%
—
—
—
—
—
—
—
—
cases:7.09%
controls:1.32%
10
32
160
1640
5
14
166
1668
—
—
—
—
9
18
118
1344
Depressive disorder
P76 [2002000870]
—
—
—
—
—
—
1.7e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.30%
controls:1.17%
—
—
—
—
—
—
8
16
119
1346
Mixed anxiety and depressive disorder
F41.2 [45566845]
9.2e-01
—
—
—
—
—
1.7e+00
cases:2.94%
controls:1.20%
—
—
—
—
—
—
—
—
—
—
cases:7.87%
controls:1.54%
5
20
165
1652
—
—
—
—
—
10
21
117
1341
Base excess in Venous blood by calculation
1927-3 [3002032]
1.7e+00
1.4e+00
—
—
—
—
1.0e+00
cases:7.06%
controls:1.38%
cases:4.68%
controls:1.19%
—
—
—
—
—
—
—
—
cases:7.87%
controls:2.94%
12
23
158
1649
8
20
163
1662
—
—
—
—
10
40
117
1322
Cystoscopy
UKC02 [2001306005]
1.7e+00
—
—
—
—
—
—
cases:6.47%
controls:1.26%
—
—
—
—
—
—
—
—
—
—
—
—
11
21
159
1651
—
—
—
—
—
—
Treatment of chronic ulcer or burn
SPAT1148 [2001700249]
1.7e+00
1.7e+00
—
—
—
—
9.1e-01
cases:5.88%
controls:1.14%
cases:3.51%
controls:0.65%
—
—
—
—
—
—
—
—
cases:3.94%
controls:1.62%
10
19
160
1653
6
11
165
1671
—
—
—
—
5
22
122
1340
Promyelocytes/Leukocytes in Blood
26524-9 [3021440]
1.5e+00
—
—
—
—
—
1.7e+00
cases:4.71%
controls:1.08%
—
—
—
—
—
—
—
—
—
—
cases:11.02%
controls:2.28%
8
18
162
1654
—
—
—
—
—
14
31
113
1331
Syncope and collapse
R55 [45568141]
1.5e+00
—
—
—
—
—
1.7e+00
cases:3.53%
controls:0.78%
—
—
—
—
—
—
—
—
—
—
cases:6.30%
controls:1.25%
6
13
164
1659
—
—
—
—
—
8
17
119
1345
Influenza virus A RNA [Presence] in Specimen by NAA with probe detection
34487-9 [3044938]
4.4e-01
8.2e-01
—
—
—
9.6e-01
1.7e+00
cases:2.94%
controls:1.91%
cases:2.92%
controls:1.31%
—
—
—
—
—
—
cases:4.40%
controls:1.73%
cases:17.32%
controls:3.82%
5
32
165
1640
5
22
166
1660
—
—
—
7
28
152
1591
22
52
105
1310
Tension-type headache
G44.2 [45581495]
1.6e+00
—
—
—
—
—
8.3e-01
cases:8.24%
controls:1.73%
—
—
—
—
—
—
—
—
—
—
cases:3.94%
controls:1.76%
14
29
156
1643
—
—
—
—
—
5
24
122
1338
One hour or less
ZXE00 [2001311394]
8.1e-01
6.9e-01
—
—
—
1.5e+00
1.6e+00
cases:11.76%
controls:5.62%
cases:3.51%
controls:1.78%
—
—
—
—
—
—
cases:5.03%
controls:1.17%
cases:14.96%
controls:3.38%
20
94
150
1578
6
30
165
1652
—
—
—
8
19
151
1600
19
46
108
1316
pH of Venous blood
2746-6 [3012544]
1.6e+00
1.4e+00
—
—
—
—
9.2e-01
cases:7.06%
controls:1.50%
cases:4.68%
controls:1.19%
—
—
—
—
—
—
—
—
cases:7.87%
controls:3.30%
12
25
158
1647
8
20
163
1662
—
—
—
—
10
45
117
1317
Myelocytes/Leukocytes in Blood
26498-6 [3017181]
1.5e+00
—
—
—
—
—
1.6e+00
cases:4.71%
controls:1.14%
—
—
—
—
—
—
—
—
—
—
cases:11.02%
controls:2.42%
8
19
162
1653
—
—
—
—
—
14
33
113
1329
Acute cystitis
N30.0 [45601724]
1.6e+00
2.0e+00
—
—
—
-1.0e+50
5.2e-01
cases:6.47%
controls:1.38%
cases:2.92%
controls:0.42%
—
—
—
—
—
—
cases:0.00%
controls:0.68%
cases:4.72%
controls:2.86%
11
23
159
1649
5
7
166
1675
—
—
—
0
11
159
1608
6
39
121
1323
Standard cardiac ultrasound examination
FM1AE [2001303278]
1.0e+00
1.6e+00
—
—
—
—
7.2e-01
cases:5.88%
controls:2.21%
cases:5.85%
controls:1.25%
—
—
—
—
—
—
—
—
cases:4.72%
controls:2.35%
10
37
160
1635
10
21
161
1661
—
—
—
—
6
32
121
1330
zopiclone; oral
N05CF01 [21604654]
7.6e-01
7.5e-01
1.6e+00
—
—
4.7e-01
8.5e-01
cases:14.71%
controls:7.48%
cases:8.77%
controls:4.34%
cases:5.85%
controls:1.25%
—
—
—
—
cases:6.29%
controls:4.01%
cases:14.17%
controls:6.61%
25
125
145
1547
15
73
156
1609
10
21
161
1661
—
—
10
65
149
1554
18
90
109
1272
Abdominal CT examination
JN3AD [2001305554]
9.2e-01
—
—
1.0e+50
—
1.9e+00
1.6e+00
cases:2.94%
controls:1.20%
—
—
—
—
cases:2.92%
controls:0.00%
—
—
cases:3.14%
controls:0.49%
cases:9.45%
controls:2.13%
5
20
165
1652
—
—
5
0
166
1682
—
5
8
154
1611
12
29
115
1333
Metamyelocytes/Leukocytes in Blood
28541-1 [3002179]
1.3e+00
—
—
—
—
—
1.6e+00
cases:3.53%
controls:0.96%
—
—
—
—
—
—
—
—
—
—
cases:10.24%
controls:2.35%
6
16
164
1656
—
—
—
—
—
13
32
114
1330
methotrexate; oral, parenteral
L04AX03 [21603929]
7.9e-01
—
—
—
—
1.3e+00
1.6e+00
cases:4.12%
controls:1.91%
—
—
—
—
—
—
—
—
cases:5.03%
controls:1.48%
cases:10.24%
controls:2.35%
7
32
163
1640
—
—
—
—
8
24
151
1595
13
32
114
1330
methotrexate
L01BA01 [21601423]
7.9e-01
—
—
—
—
1.3e+00
1.6e+00
cases:4.12%
controls:1.91%
—
—
—
—
—
—
—
—
cases:5.03%
controls:1.48%
cases:10.24%
controls:2.35%
7
32
163
1640
—
—
—
—
8
24
151
1595
13
32
114
1330
phenoxymethylpenicillin; oral
J01CE02 [21602842]
7.2e-01
6.0e-01
—
—
-1.0e+50
9.2e-01
8.3e-01
cases:25.29%
controls:14.17%
cases:6.43%
controls:3.63%
—
—
—
—
cases:0.00%
controls:0.48%
cases:7.55%
controls:3.15%
cases:22.05%
controls:11.01%
43
237
127
1435
11
61
160
1621
—
—
0
8
170
1672
12
51
147
1568
28
150
99
1212
benzathine phenoxymethylpenicillin; oral
J01CE10 [21602850]
7.2e-01
6.0e-01
—
—
-1.0e+50
9.2e-01
8.3e-01
cases:25.29%
controls:14.17%
cases:6.43%
controls:3.63%
—
—
—
—
cases:0.00%
controls:0.48%
cases:7.55%
controls:3.15%
cases:22.05%
controls:11.01%
43
237
127
1435
11
61
160
1621
—
—
0
8
170
1672
12
51
147
1568
28
150
99
1212
Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction
14804-9 [3022250]
8.8e-01
1.1e+00
—
—
—
9.6e-01
1.5e+00
cases:3.53%
controls:1.50%
cases:4.09%
controls:1.43%
—
—
—
—
—
—
cases:3.77%
controls:1.48%
cases:9.45%
controls:2.20%
6
25
164
1647
7
24
164
1658
—
—
—
6
24
153
1595
12
30
115
1332
Other specified chronic obstructive pulmonary disease
J44.8 [45586673]
1.5e+00
1.5e+00
—
1.0e+50
—
1.4e+00
5.3e-01
cases:7.06%
controls:1.61%
cases:3.51%
controls:0.83%
—
—
cases:3.51%
controls:0.00%
—
—
cases:4.40%
controls:1.17%
cases:3.94%
controls:2.35%
12
27
158
1645
6
14
165
1668
—
6
0
165
1682
—
7
19
152
1600
5
32
122
1330
betamethasone
A07EA04 [21600656]
6.0e-01
1.2e+00
—
—
—
1.5e+00
6.2e-01
cases:11.76%
controls:6.82%
cases:6.43%
controls:2.02%
—
—
—
—
—
—
cases:10.06%
controls:2.41%
cases:11.02%
controls:6.24%
20
114
150
1558
11
34
160
1648
—
—
—
16
39
143
1580
14
85
113
1277
betamethasone
S02BA07 [21605169]
6.0e-01
1.2e+00
—
—
—
1.5e+00
6.2e-01
cases:11.76%
controls:6.82%
cases:6.43%
controls:2.02%
—
—
—
—
—
—
cases:10.06%
controls:2.41%
cases:11.02%
controls:6.24%
20
114
150
1558
11
34
160
1648
—
—
—
16
39
143
1580
14
85
113
1277
betamethasone
C05AA05 [21601610]
6.0e-01
1.2e+00
—
—
—
1.5e+00
6.2e-01
cases:11.76%
controls:6.82%
cases:6.43%
controls:2.02%
—
—
—
—
—
—
cases:10.06%
controls:2.41%
cases:11.02%
controls:6.24%
20
114
150
1558
11
34
160
1648
—
—
—
16
39
143
1580
14
85
113
1277
betamethasone
D07AC01 [21602120]
6.0e-01
1.2e+00
—
—
—
1.5e+00
6.2e-01
cases:11.76%
controls:6.82%
cases:6.43%
controls:2.02%
—
—
—
—
—
—
cases:10.06%
controls:2.41%
cases:11.02%
controls:6.24%
20
114
150
1558
11
34
160
1648
—
—
—
16
39
143
1580
14
85
113
1277
Tissue transglutaminase IgA Ab [Units/volume] in Serum
31017-7 [3019050]
8.3e-01
1.5e+00
—
—
—
1.3e+00
8.9e-01
cases:8.82%
controls:4.07%
cases:7.60%
controls:1.78%
—
—
—
—
—
—
cases:5.03%
controls:1.36%
cases:12.60%
controls:5.58%
15
68
155
1604
13
30
158
1652
—
—
—
8
22
151
1597
16
76
111
1286
Essential (primary) hypertension
I10 [45591453]
6.3e-01
7.5e-01
1.1e+00
—
1.2e+00
8.7e-01
4.5e-01
cases:27.65%
controls:16.93%
cases:16.37%
controls:8.44%
cases:4.09%
controls:1.37%
—
—
cases:6.47%
controls:2.02%
cases:20.13%
controls:9.51%
cases:28.35%
controls:20.12%
47
283
123
1389
28
142
143
1540
7
23
164
1659
—
11
34
159
1646
32
154
127
1465
36
274
91
1088
Extended examination of mouth
SAA03 [2001310276]
5.2e-01
9.0e-01
—
—
—
1.5e+00
5.4e-01
cases:12.94%
controls:8.13%
cases:4.68%
controls:1.96%
—
—
—
—
—
—
cases:6.29%
controls:1.48%
cases:10.24%
controls:6.24%
22
136
148
1536
8
33
163
1649
—
—
—
10
24
149
1595
13
85
114
1277
Blasts/Leukocytes in Blood
26446-5 [3025159]
1.5e+00
—
—
—
—
1.2e+00
1.5e+00
cases:4.12%
controls:0.96%
—
—
—
—
—
—
—
—
cases:3.14%
controls:0.93%
cases:10.24%
controls:2.50%
7
16
163
1656
—
—
—
—
5
15
154
1604
13
34
114
1328
doxycycline; oral, parenteral
J01AA02 [21602800]
7.1e-01
7.7e-01
—
—
—
3.2e-02
7.6e-01
cases:27.65%
controls:15.85%
cases:8.77%
controls:4.28%
—
—
—
—
—
—
cases:5.03%
controls:4.88%
cases:25.20%
controls:13.66%
47
265
123
1407
15
72
156
1610
—
—
—
8
79
151
1540
32
186
95
1176
Pain localized to upper abdomen
R10.1 [45568111]
1.1e+00
—
—
—
—
—
1.5e+00
cases:5.88%
controls:2.09%
—
—
—
—
—
—
—
—
—
—
cases:12.60%
controls:3.23%
10
35
160
1637
—
—
—
—
—
16
44
111
1318
Exposure to unspecified factor
X59 [45756412]
1.0e+00
1.8e+00
—
—
—
1.8e+00
1.4e+00
cases:4.12%
controls:1.50%
cases:2.92%
controls:0.48%
—
—
—
—
—
—
cases:3.14%
controls:0.56%
cases:7.87%
controls:1.98%
7
25
163
1647
5
8
166
1674
—
—
—
5
9
154
1610
10
27
117
1335
HIV 1 and 2 tests - Meaningful Use set
75622-1 [46235355]
5.2e-01
1.2e+00
—
—
—
1.4e+00
7.5e-01
cases:5.88%
controls:3.59%
cases:5.85%
controls:1.90%
—
—
—
—
—
—
cases:6.92%
controls:1.73%
cases:9.45%
controls:4.70%
10
60
160
1612
10
32
161
1650
—
—
—
11
28
148
1591
12
64
115
1298
Functional capacity evaluation
443351003 [40481051]
1.4e+00
8.7e-01
—
—
—
-1.0e+50
—
cases:10.00%
controls:2.57%
cases:2.92%
controls:1.25%
—
—
—
—
—
—
cases:0.00%
controls:0.86%
—
—
17
43
153
1629
5
21
166
1661
—
—
—
0
14
159
1605
—
sulfadiazine and trimethoprim
J01EE02 [21602962]
1.4e+00
—
—
—
—
—
9.1e-01
cases:8.82%
controls:2.27%
—
—
—
—
—
—
—
—
—
—
cases:6.30%
controls:2.64%
15
38
155
1634
—
—
—
—
—
8
36
119
1326
venlafaxine; oral
N06AX16 [21604745]
1.4e+00
8.7e-01
—
—
—
—
5.0e-01
cases:7.65%
controls:1.97%
cases:2.92%
controls:1.25%
—
—
—
—
—
—
—
—
cases:3.94%
controls:2.42%
13
33
157
1639
5
21
166
1661
—
—
—
—
5
33
122
1329
Administration of medicine
SPAT1254 [2001700355]
1.4e+00
1.7e+00
—
-1.0e+50
—
—
1.4e+00
cases:7.65%
controls:1.97%
cases:3.51%
controls:0.65%
—
—
cases:0.00%
controls:0.30%
—
—
—
—
cases:6.30%
controls:1.69%
13
33
157
1639
6
11
165
1671
—
0
5
171
1677
—
—
8
23
119
1339
Influenza virus B RNA [Presence] in Specimen by NAA with probe detection
40982-1 [3038288]
—
1.1e+00
—
—
—
9.5e-01
1.4e+00
—
—
cases:2.92%
controls:1.01%
—
—
—
—
—
—
cases:3.14%
controls:1.24%
cases:11.02%
controls:2.94%
—
5
17
166
1665
—
—
—
5
20
154
1599
14
40
113
1322
ABO and Rh group [Type] in Blood by Confirmatory method
77397-8 [46236098]
-3.7e-01
1.4e+00
—
—
—
1.5e+00
8.0e-01
cases:3.53%
controls:5.02%
cases:8.19%
controls:2.14%
—
—
—
—
—
—
cases:5.66%
controls:1.36%
cases:11.02%
controls:5.29%
6
84
164
1588
14
36
157
1646
—
—
—
9
22
150
1597
14
72
113
1290
pH of Specimen
17433-4 [3019225]
—
—
—
—
—
—
1.4e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.87%
controls:2.06%
—
—
—
—
—
—
10
28
117
1334
Physiotherapist
Z3226 [2001311560]
1.4e+00
—
—
—
—
—
—
cases:6.47%
controls:1.67%
—
—
—
—
—
—
—
—
—
—
—
—
11
28
159
1644
—
—
—
—
—
—
Respiratory syncytial virus RNA [Identifier] in Specimen by NAA with probe detection
40987-0 [3043924]
—
1.0e+00
—
—
—
1.0e+00
1.4e+00
—
—
cases:2.92%
controls:1.07%
—
—
—
—
—
—
cases:3.14%
controls:1.17%
cases:11.02%
controls:3.01%
—
5
18
166
1664
—
—
—
5
19
154
1600
14
41
113
1321
Cyclic citrullinated peptide Ab [Units/volume] in Serum
53027-9 [3041942]
7.3e-01
1.3e+00
—
—
—
1.5e+00
1.4e+00
cases:7.06%
controls:3.53%
cases:4.09%
controls:1.13%
—
—
—
—
—
—
cases:3.14%
controls:0.74%
cases:12.60%
controls:3.52%
12
59
158
1613
7
19
164
1663
—
—
—
5
12
154
1607
16
48
111
1314
Fungus identified in Specimen by Culture
580-1 [3000494]
2.4e-01
1.1e+00
—
—
—
—
1.4e+00
cases:2.94%
controls:2.33%
cases:2.92%
controls:0.95%
—
—
—
—
—
—
—
—
cases:11.81%
controls:3.30%
5
39
165
1633
5
16
166
1666
—
—
—
—
15
45
112
1317
oxycodone and naloxone; oral
N02AA55 [21604265]
9.6e-01
—
—
—
—
1.3e+00
1.4e+00
cases:6.47%
controls:2.57%
—
—
—
—
—
—
—
—
cases:3.77%
controls:1.05%
cases:11.02%
controls:3.08%
11
43
159
1629
—
—
—
—
6
17
153
1602
14
42
113
1320

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
63
12
76.36
113.93
2.3
1.4
46.22
23.76
ng/l
0.78
63
12
113
166
14.44
83.34
5.9
1.7
250.17
382.96
nmol/l
5.81
103
153
28
37
8.64
20.50
1.8
1.2
11.09
9.36
u/l
0.14
19
28
50
131
4.76
18.33
4.8
2.9
1.23
1.23
mmol/l
0.20
45
106
86
339
3.71
17.90
3.8
3.0
471.63
521.92
mosm/kgh2o
1.51
78
295
52
146
4.47
17.42
4.0
3.8
0.05
0.15
%
0.57
19
41
139
771
3.66
16.40
21.2
14.2
1.21
1.22
inr
0.08
121
641
52
158
4.10
15.55
4.0
3.6
0.79
0.92
%
0.17
19
53
49
143
4.22
15.47
2.7
2.4
9.83
10.49
g/l
0.35
44
134
144
839
3.59
15.23
11.7
6.5
1.22
1.21
mmol/l
1.45
115
734
49
149
4.04
14.57
4.2
4.3
0.00
0.31
%
0.74
14
39
98
465
3.18
14.48
5.9
4.4
—
—
—
0
0
40
105
4.52
14.44
5.5
3.4
4.74
4.52
pmol/l
0.55
33
91
23
17
15.12
14.13
1.6
1.2
—
—
nmol/l
—
0
0
25
44
6.35
14.06
3.2
2.4
7.42
7.42
ph
0.16
25
44
108
570
2.96
12.78
8.0
5.7
—
—
—
0
0
47
152
3.74
12.69
3.8
3.5
0.44
0.65
%
0.41
16
49
23
22
11.66
12.64
1.5
1.2
0.19
0.17
nmol/l
0.37
17
16
102
528
2.91
12.42
5.8
2.6
56.82
62.07
u/l
0.24
96
495
128
754
2.96
12.13
11.9
5.9
1.22
1.21
mmol/l
0.88
119
695
38
109
4.07
12.12
4.6
4.8
7.43
7.42
ph
0.26
29
87
23
24
10.68
12.12
2.8
2.0
—
—
—
0
0
134
814
2.98
11.90
8.6
5.7
2.43
2.82
%
1.19
128
763
134
819
2.95
11.68
8.7
5.9
8.57
8.63
%
0.09
129
771
129
775
2.89
11.57
4.4
2.4
76.40
76.69
nmol/l
0.04
119
708
22
26
9.37
10.87
3.1
2.2
5.05
5.00
kpa
0.11
22
26
22
26
9.37
10.87
3.1
2.2
9.06
9.15
kpa
0.05
22
26
82
402
2.77
10.74
5.2
4.9
—
—
—
0
0
61
261
2.93
10.25
1.9
2.0
28.77
29.18
s
0.29
53
254
137
882
2.78
10.20
8.2
6.1
0.04
0.04
e9/l
0.49
124
748
36
112
3.70
10.18
4.2
3.0
82.36
74.04
ng/l
0.19
28
102
35
107
3.76
10.15
10.4
9.4
24.69
25.07
mmol/l
0.20
35
107
96
521
2.63
10.13
7.8
3.4
7.39
7.40
ph
0.50
79
359
21
26
8.89
10.13
1.3
2.4
16.93
16.17
%
0.41
21
26
35
108
3.72
10.01
4.5
2.4
10.87
13.09
nmol/l
0.58
29
102
40
135
3.46
10.00
6.3
3.5
—
—
—
0
0
81
407
2.67
9.97
4.1
2.8
7.27
5.18
e6/l
0.64
72
372
136
879
2.73
9.94
8.3
6.0
0.62
0.57
e9/l
1.73
124
747
138
905
2.71
9.68
8.2
6.0
1.92
2.01
e9/l
0.31
129
794
103
588
2.56
9.66
4.7
3.4
20.72
174.68
e6/l
0.76
87
440
138
915
2.66
9.29
8.5
6.2
0.16
0.19
e9/l
1.50
126
792
36
119
3.47
9.26
1.5
1.2
72.00
128.67
u/ml
—
10
49
55
234
2.87
9.25
1.6
1.3
—
—
—
0
0
44
165
3.14
9.24
4.3
4.6
7.38
7.38
ph
0.20
28
90
93
523
2.46
8.80
3.0
2.1
133.44
155.87
u/l
0.38
87
501
78
405
2.52
8.77
2.4
1.7
0.73
1.16
mg/l
1.40
56
322
33
107
3.50
8.73
1.2
2.6
—
—
—
0
0
108
653
2.43
8.66
6.0
3.8
29.00
35.95
ng/l
0.34
89
448
99
578
2.42
8.56
3.5
3.3
2.33
2.35
mmol/l
0.65
94
534
21
50
4.58
8.43
5.9
6.4
8.60
8.33
kpa
0.32
21
50
109
670
2.39
8.31
5.5
4.1
50.19
68.24
e6/l
0.28
89
459
115
726
2.38
8.22
2.4
2.1
96.57
97.03
pmol/l
0.03
71
387
16
18
9.56
8.21
1.7
1.1
—
—
—
0
0
68
340
2.52
8.19
2.4
1.7
465.41
17361562.74
pmol/l
0.50
58
288
15
15
10.71
8.18
1.2
1.7
90.77
90.83
%
0.01
15
15
42
164
2.98
8.18
4.3
4.5
2.26
1.80
mmol/l
0.41
34
140
59
277
2.61
8.09
4.4
3.0
0.80
0.82
mmol/l
0.67
59
266
59
277
2.61
8.09
3.3
2.2
2.28
2.31
g/l
0.13
53
254
88
500
2.36
7.95
4.5
3.3
0.26
0.58
e6/l
0.92
70
353
142
998
2.48
7.76
9.7
9.5
4.60
4.10
e9/l
1.79
134
861
135
932
2.39
7.61
10.9
6.3
10.97
11.71
umol/l
0.18
127
890
170
1312
3.03
7.49
15.1
8.0
78.88
78.78
u/l
0.01
160
1239
25
78
3.52
6.97
1.5
1.3
—
1.62
—
0
6
125
855
2.24
6.92
5.3
2.9
152.94
105.14
ug/l
1.34
116
804
53
253
2.49
6.92
3.5
2.2
22.37
21.83
%
0.09
48
237
76
429
2.25
6.75
3.2
2.1
2.80
2.86
mg/l
0.09
69
372
40
168
2.73
6.75
4.4
4.6
5.89
5.71
kpa
0.67
40
163
54
263
2.45
6.73
1.7
1.4
497.14
530.17
titre
0.06
14
59
25
80
3.43
6.71
5.3
5.2
—
—
—
0
0
118
796
2.19
6.67
17.7
11.2
0.00
0.00
e9/l
0.68
107
654
52
252
2.44
6.54
2.5
1.6
1281.42
1164.79
nmol/l
0.36
42
189
19
51
4.01
6.53
2.6
2.6
26.68
24.88
mmol/l
0.98
19
51
58
296
2.35
6.50
3.6
2.2
12.61
12.69
umol/l
0.03
53
277
27
94
3.17
6.34
1.7
1.3
23.03
25.12
iu/l
0.10
21
83
49
236
2.43
6.22
3.5
2.4
115.72
104.54
ug/g
0.15
32
184
12
14
9.04
6.15
2.5
2.6
5.85
3.23
nmol/l
0.48
12
14
47
224
2.44
6.10
5.5
7.8
102.74
103.85
mmol/l
0.64
47
224
74
429
2.15
6.04
1.8
1.4
2.25
2.33
g/l
0.19
54
265
42
192
2.51
5.95
2.4
1.6
—
—
—
0
0
58
309
2.24
5.81
5.1
3.5
50.70
163.90
ng/l
0.62
43
233
14
24
6.19
5.64
2.0
1.8
5.09
7.34
pmol/l
1.48
14
24
59
320
2.20
5.64
1.7
2.0
—
—
—
0
0
167
1342
2.52
5.61
9.0
4.4
14.93
14.60
pmol/l
1.02
161
1227
18
52
3.71
5.60
1.2
3.8
21.56
39.08
mg/l
2.19
12
47
41
191
2.44
5.56
11.6
7.5
1.21
1.14
mmol/l
0.04
35
156
15
30
5.32
5.38
2.9
2.1
91.51
90.86
%
0.19
15
30
30
122
2.72
5.35
1.2
1.5
—
—
—
0
0
5
0
+∞
5.23
10.0
0.0
2.00
—
nmol/l
—
5
0
9
9
10.40
5.08
2.0
3.2
65.67
62.00
nmol/l
—
9
9
48
249
2.22
5.07
2.6
2.0
—
—
—
0
0
40
192
2.36
5.06
12.0
7.5
7.42
7.42
ph
0.01
25
124
15
41
3.88
5.03
3.9
2.6
60.67
61.51
%
0.08
15
41
45
230
2.24
4.91
3.9
3.1
3.92
5.59
e9/l
0.93
39
202
17
52
3.48
4.87
1.2
3.8
24.88
25.06
mg/l
0.01
11
46
82
531
1.93
4.70
6.9
3.3
0.05
0.01
estimate
0.41
38
147
73
457
1.94
4.61
1.7
1.3
0.94
1.12
u/ml
0.16
23
127
7
5
14.43
4.61
1.4
4.8
58.36
50.60
%
—
7
5
13
27
5.07
4.59
3.6
3.3
4.77
5.01
e9/l
0.10
13
27
80
521
1.90
4.46
6.6
4.2
0.00
0.00
estimate
-0.00
45
174
39
197
2.22
4.36
1.6
2.7
1.75
1.81
%
0.13
33
176
13
29
4.72
4.33
1.1
5.4
—
—
—
0
0
82
544
1.86
4.28
3.4
3.1
8.30
7.92
mmol/l
0.23
70
450
76
493
1.88
4.25
2.2
1.7
19.71
20.31
nmol/l
0.12
68
415
81
538
1.85
4.20
4.9
3.1
—
—
—
0
0
39
202
2.16
4.09
1.3
1.6
—
—
—
0
0
15
48
3.30
4.02
1.1
3.6
1.03
2.35
ratio
—
7
29
60
366
1.92
4.02
1.8
1.3
48.98
27.55
iu/ml
0.31
14
112
18
65
2.95
3.97
1.3
1.4
—
—
—
0
0
78
520
1.82
3.95
4.6
3.7
8.56
8.77
mg/mmol
0.01
43
327
30
143
2.29
3.83
1.7
2.8
71.07
70.97
e9/l
0.00
23
103
43
238
2.03
3.78
2.0
1.3
—
—
—
0
0
49
286
1.95
3.71
1.3
1.6
—
—
—
0
0
28
132
2.30
3.67
11.7
9.2
—
—
—
0
0
188
1685
3.09
3.57
43.3
17.3
139.30
139.67
mmol/l
1.02
183
1651
13
36
3.79
3.57
1.2
1.4
122.38
315.41
u/ml
—
8
17
81
561
1.75
3.52
4.9
3.4
—
—
—
0
0
188
1688
3.06
3.50
43.2
17.4
3.91
3.96
mmol/l
1.76
183
1651
7
10
7.21
3.39
1.6
1.7
137.29
140.40
nmol/l
—
7
10
104
782
1.69
3.29
3.5
2.7
—
—
estimate
—
0
0
46
273
1.89
3.29
3.5
3.1
4.39
2.80
e6/l
0.53
29
117
22
99
2.37
3.20
6.4
4.0
—
—
—
0
0
177
1564
2.19
3.11
9.1
5.9
41.26
38.71
mmol/mol
2.18
170
1474
19
82
2.46
3.02
1.2
1.1
—
—
—
0
0
186
1682
2.62
3.01
36.2
15.2
21.87
23.29
mg/l
0.31
168
1369
96
720
1.64
2.98
7.4
3.9
0.05
0.01
estimate
0.40
41
153
175
1548
2.08
2.93
10.0
5.4
1.69
1.87
mu/l
1.18
165
1440
7
13
5.54
2.89
1.1
1.1
—
—
—
0
0
6
9
6.83
2.89
1.3
1.3
1895.00
1714.44
ml
—
6
9
72
507
1.66
2.83
3.5
3.2
57.94
48.48
mg/l
0.09
45
335
62
424
1.67
2.71
2.7
2.8
328.79
339.72
umol/l
0.36
56
375
76
548
1.63
2.70
3.3
2.2
—
—
—
0
0
10
30
3.45
2.64
4.8
2.5
—
—
—
0
0
16
68
2.47
2.63
1.9
1.9
0.72
5.41
ug/l
0.60
16
61
5
7
7.29
2.56
1.0
1.0
—
—
—
0
0
177
1592
2.01
2.51
6.5
4.8
6.01
5.85
mmol/l
0.59
165
1483
8
21
3.92
2.49
3.3
3.1
1.19
1.19
mmol/l
—
8
21
19
90
2.23
2.48
2.9
4.8
0.58
0.59
%
0.05
19
90
8
22
3.74
2.39
2.8
2.3
—
—
—
0
0
8
22
3.74
2.39
3.3
3.0
105.38
106.09
mmol/l
—
8
22
8
22
3.74
2.39
3.3
3.0
4.01
3.99
mmol/l
—
8
22
5
8
6.37
2.38
1.2
1.8
4.26
2.96
mg/l
—
5
8
5
8
6.37
2.38
1.4
1.1
—
—
g/l
—
0
0
11
39
2.92
2.38
5.8
4.5
—
—
—
0
0
19
92
2.18
2.36
2.9
4.8
0.83
1.34
%
2.13
19
92
68
492
1.58
2.33
1.5
1.5
—
—
—
0
0
51
346
1.64
2.27
1.8
1.3
21.56
8.21
u/ml
0.27
14
128
20
101
2.09
2.25
1.5
1.2
—
—
—
0
0
10
35
2.95
2.24
1.3
1.1
—
—
—
0
0
5
9
5.66
2.22
1.4
1.2
4.52
7.58
ug/l
—
5
9
8
24
3.43
2.20
1.4
2.4
33.13
32.92
pg
—
8
24
34
212
1.73
2.06
1.8
1.4
—
—
—
0
0
115
954
1.49
2.00
7.3
4.0
0.02
8.55
estimate
0.50
48
190
114
945
1.48
1.98
7.1
4.0
0.00
0.00
estimate
-0.00
47
185
8
27
3.04
1.96
1.1
1.1
—
—
—
0
0
6
16
3.83
1.95
1.2
1.1
—
—
—
0
0
9
34
2.72
1.89
1.1
1.6
—
—
—
0
0
8
28
2.93
1.88
1.3
1.7
—
—
—
0
0
8
28
2.93
1.88
1.3
1.8
—
—
—
0
0
8
28
2.93
1.88
1.3
1.7
—
—
—
0
0
8
28
2.93
1.88
1.3
1.8
—
—
—
0
0
6
17
3.60
1.85
2.7
3.5
—
—
—
0
0
5
12
4.24
1.83
1.0
1.0
306.00
292.83
mg/l
—
5
12
9
36
2.57
1.76
1.7
1.5
—
—
—
0
0
28
173
1.72
1.76
5.3
2.5
29.61
29.28
u/l
0.03
23
145
49
350
1.53
1.73
2.5
2.8
2.49
2.44
mmol/l
1.55
40
316
5
13
3.92
1.72
4.8
1.9
92.80
69.77
umol/l
—
5
13
12
56
2.22
1.64
2.1
1.4
283.14
297.04
ug/g
—
7
32
114
967
1.42
1.63
7.4
4.0
0.09
0.02
estimate
0.33
43
177
8
32
2.56
1.61
3.0
1.5
182.38
206.11
pmol/l
—
8
27
6
20
3.06
1.59
4.3
5.5
14.12
14.03
mg/l
—
6
20
135
1185
1.43
1.56
6.8
3.2
62.34
42.13
u/l
1.17
122
1122
0
42
0.00
1.54
0.0
1.5
—
—
—
0
0
11
51
2.22
1.53
1.5
1.2
—
—
—
0
0
7
27
2.65
1.53
1.3
1.1
—
—
—
0
0
0
45
0.00
1.52
0.0
1.6
—
—
—
0
0
90
740
1.39
1.50
2.0
1.9
1.59
1.34
mmol/l
1.34
75
619
91
750
1.39
1.50
5.1
3.6
6.40
6.19
ph
0.97
61
431
54
412
1.43
1.37
6.6
4.2
1.02
1.02
kg/l
0.11
40
276
169
1564
1.53
1.35
5.0
4.2
1.48
1.24
mmol/l
3.06
151
1456
23
146
1.65
1.33
1.3
1.2
—
—
—
0
0
0
41
0.00
1.32
0.0
1.5
—
1.26
—
0
30
14
77
1.88
1.29
3.9
4.6
36.97
36.96
°c
0.09
14
77
14
77
1.88
1.29
2.4
2.0
—
—
—
0
0
8
35
2.34
1.28
2.1
3.8
65.88
56.48
%
—
8
35
15
85
1.83
1.27
5.4
3.6
1.02
1.02
ratio
1.02
15
80
6
25
2.44
1.25
2.0
1.3
—
—
—
0
0
5
20
2.54
1.16
1.0
1.3
—
—
—
0
0
182
1725
1.64
1.15
32.6
13.1
—
—
—
0
0
82
688
1.33
1.13
2.6
2.1
—
—
—
0
0
32
229
1.47
1.13
1.4
1.3
—
—
—
0
0
24
162
1.55
1.10
1.5
1.4
—
—
—
0
0
14
85
1.70
0.97
2.6
1.6
0.16
0.30
mg/l
—
8
32
174
1648
1.44
0.93
6.0
5.0
4.63
4.68
mmol/l
0.30
162
1547
11
63
1.79
0.92
1.6
1.5
—
—
—
0
0
173
1639
1.42
0.90
5.9
4.9
1.44
1.51
mmol/l
1.25
158
1531
6
30
2.03
0.87
2.3
1.6
3.67
4.19
u/ml
—
6
30
81
700
1.27
0.85
3.7
3.2
—
—
—
0
0
11
65
1.73
0.84
1.6
1.5
—
—
—
0
0
175
1667
1.41
0.82
6.4
5.6
2.66
2.74
mmol/l
0.65
162
1560
11
67
1.68
0.77
1.4
1.5
—
—
—
0
0
11
67
1.68
0.77
1.6
1.5
—
—
—
0
0
9
54
1.70
0.75
1.2
1.2
—
—
—
0
0
11
68
1.65
0.73
1.7
1.5
—
—
—
0
0
188
1821
1.59
0.73
49.4
22.9
7.56
6.75
e9/l
5.14
183
1785
188
1821
1.59
0.73
49.3
22.8
4.46
4.47
e12/l
0.18
183
1786
61
520
1.25
0.71
8.4
6.5
—
—
—
0
0
0
20
0.00
0.60
0.0
5.1
—
10.53
—
0
20
17
124
1.41
0.58
1.2
1.3
—
—
—
0
0
8
55
1.47
0.57
1.5
1.2
—
—
—
0
0
10
65
1.57
0.56
2.9
2.9
—
—
—
0
0
23
178
1.33
0.56
1.6
1.9
—
—
—
0
0
21
168
1.28
0.42
2.0
2.3
0.00
0.00
estimate
—
9
41
0
15
0.00
0.41
0.0
1.1
—
—
—
0
0
7
105
0.65
0.40
1.6
1.8
—
—
—
0
0
0
19
0.00
0.39
0.0
2.9
—
—
—
0
0
16
125
1.30
0.38
2.2
2.3
10.44
4.88
ug/l
0.49
16
113
0
11
0.00
0.21
0.0
1.5
—
—
—
0
0
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
11
89
1.25
0.21
1.2
1.1
—
—
—
0
0
5
68
0.73
0.17
1.0
1.1
1.47
1.63
g/l
—
5
68
49
461
1.08
0.15
6.1
5.5
3.01
2.61
ug/l
0.10
41
418
19
208
0.90
0.11
1.3
1.5
—
—
—
0
0
27
278
0.97
0.02
2.8
3.2
2.10
0.72
ug/l
0.50
17
183
0
6
0.00
0.00
0.0
4.0
—
37.17
—
0
6
0
9
0.00
0.00
0.0
1.1
—
—
—
0
0
0
9
0.00
0.00
0.0
1.8
—
—
—
0
0
0
9
0.00
0.00
0.0
1.7
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
6
69
0.87
-0.00
1.2
1.1
0.96
0.92
g/l
—
6
69
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
5
51
0.98
-0.00
4.8
1.7
—
—
—
0
0
8
80
1.00
-0.00
1.0
1.2
—
—
—
0
0
18
180
1.00
-0.00
1.4
1.6
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.6
—
—
—
0
0

Mortality – FinRegistry

↥

Association

Association between endpoint E4_ADRENAS and mortality.

Females

Parameter HR [95% CI] p-value
E4_ADRENAS 2.633 [1.78, 3.89] < 0.001
Birth year 0.998 [0.99, 1.01] 0.58

During the follow-up period (1.1.1998 — 31.12.2019), 81 out of 411 females with E4_ADRENAS died.

Males

Parameter HR [95% CI] p-value
E4_ADRENAS 2.646 [1.65, 4.25] < 0.001
Birth year 0.987 [0.98, 1.0] 0.007

During the follow-up period (1.1.1998 — 31.12.2019), 69 out of 264 males with E4_ADRENAS died.

Mortality risk

Mortality risk for people of age

years, who have E4_ADRENAS.

N-year risk Females Males
1 0.191% 0.525%
5 1.462% 3.045%
10 3.893% 7.638%
15 7.674% 14.4%
20 13.363% 23.783%

Relationships between endpoints

↥

Index endpoint: E4_ADRENAS – Disorders of adrenal gland, other and/or unspecified

GWS hits: 1

Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
loading spinner Loading data